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1 Introduction 
1.1 Catecholaminergic polymorphic ventricular tachycardia 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmic genetic 
cardiac disorder first described by Reid et al. (Reid et al. 1975). CPVT results from 
abnormal calcium (Ca2+) handling in cardiomyocytes (CMs), which leads to syncope, 
ventricular tachycardia and sudden cardiac death at young age without structural alterations 
of the heart. The majority of patients carry mutations in the gene of cardiac ryanodine 
receptor (RyR2) forming the calcium release channel in the sarcoplasmic reticulum (SR). 
The defect causes spontaneous Ca2+ leak during diastole. However, the pathomechanism of 
the disease is not fully understood. 
1.1.1 Epidemiology  
CPVT is one of the most severe and lethal hereditary channelopathies with an estimated 
prevalence of 1:10 000 in Europe (Napolitano and Priori 2007; Hayashi et al. 2009). The 
mean age of onset of symptoms is 7-9 years. In exceptional cases the first syncope may 
occur during adulthood (Cerrone et al. 2009). Following Priori’s data, 30% of the patients 
develop symptoms before the age of 10 and 60% of patients have approximately at least 
one syncopal episode before the age of 40. According to the PACES study which included 
226 children with CPVT, 78% were symptomatic before the diagnoses were made (van der 
Werf and Wilde 2015). Because of the lack of systematic assessment in the population, 
realistic epidemiological data is not available. 
1.1.2 Clinical presentation 
The initial manifestation of CPVT is syncope triggered by physical or emotional stress 
during the first or second decade of life. In 30% of the cases a family history of fainting 
with seizure-like activity, exercise-related syncope or sudden cardiac death is known, which 
can lead to the diagnosis of CPVT (Sumitomo et al. 2003). Because of seizures epilepsy is 
often diagnosed leading to a delay in diagnosis of approximately 2 years and a mistreatment 
with antiepileptic drugs.  
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CPVT is an autosomal dominant disease (depending on the localization of the mutation). A 
family screening is necessary because asymptomatic carriers of a RyR2 mutation are often 
detected due to family screening of an index patient (Leenhardt et al. 2012). 
1.1.3 Diagnosis 
An early accurate diagnosis of CPVT leads to the best possible clinical results in patients. 
The standard diagnosis procedures to prove CPVT are the exercise test, implantable loop 
recorder, holter monitoring as well as isoproterenol infusion to mimic an adrenergic flush. 
This can induce CPVT by ventricular arrhythmias, which appear progressively after a heart 
rate threshold around 120-130 beats per minute (bpm) (Leenhardt et al. 2012). 
The QT interval in resting electrocardiogram (ECG) is usually normal for CPVT patients. 
The majority of the patients have bradycardia (≤ 60 bpm) compared with the normal heart 
rate of children, which is around 80-100 bpm.  
CPVT can be reported by holter monitoring, which shows the acceleration of the sinus 
rhythm. The arrhythmias appear beyond a sinoatrial rate threshold of 120 to 130 bpm. 
First, isolated and monomorphic ventricular premature beats appear, which increase 
correlating to the heart rate in a quadrigeminy, trigeminy and bigeminy pattern. In the end 
phase they become polymorphic and finally they form bursts with monomorphic and 
bidirectional salvoes (Sumitomo et al. 2003). In the severe stage a bidirectional ventricular 
tachycardia (with a right bundle-branch block pattern, alternating right and left QRS axis 
deviation) is reported. Bursts of rapid irregular and polymorphic ventricular tachycardia 
(350-400 bpm) can be recorded. The final stage leads to syncope. The arrhythmic activity 
can be stopped in an early stage by itself and disappear in reverse order without clinical 
symptoms. The tachycardia can be reproduced by exercise-tests or isoproterenol infusions 
(Leenhardt et al. 1995). Cardiac imaging such as ECG or cardiac magnetic resonance 
imaging does not show structural abnormalities of the heart.  
Guidelines to diagnose CPVT were developed by several experts and declared in the expert 
consensus statement on inherited primary arrhythmia syndromes. CPVT is diagnosed 
according to the expert consensus following the four definitions:  
First, CPVT is diagnosed in the presence of a structurally normal heart, normal ECG and 
unexplained exercise or catecholamine-induced bidirectional ventricular tachycardia (VT) 
or polymorphic ventricular premature beats or VT in an individual ≤ 40 years of age. 
Second, it is diagnosed in patients (index case or family member) who have a pathogenic 
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mutation. Third, it is diagnosed in family members of a CPVT index case with a normal 
heart, who manifest exercise-induced premature ventricular contractions (PVCs) or 
bidirectional polymorphic VT. Fourth, it is diagnosed in the presence of a structurally 
normal heart and coronary arteries, normal ECG and unexplained exercise or 
catecholamine-induced bidirectional VT or polymorphic ventricular premature beats or VT 
in an individual >40 years of age (Priori et al. 2013). 
1.1.4 Treatment of CPVT 
The standard therapy for CPVT patients is the administration of β-blockers to prevent 
cardiac events like ventricular ectopy or arrhythmias. To improve the medical therapy 
further anti-arrhythmic drugs such as flecainide, a class Ic antiarrhythmic agent or Ca2+-
antagonist Verapamil can be added to the standard therapy. If the patient does not respond 
to medical treatment, an implantable cardioverter defibrillator (ICD) or left cardiac 
sympathetic denervation (LCSD) should be considered to complement the medical 
treatment (Priori et al. 2013; De Ferrari et al. 2015). 
LCSD is a surgical treatment for CPVT patients, which treats refractory cardiac events and 
decreases the annual refractory cardiac events in 87% of the patients (Olde Nordkamp et 
al. 2014). New data show a benefit of the LCSD treatment. This causes the discussion if an 
ICD implantation should still be preferred towards LCSD treatment as first-line therapy for 
high-risk CPVT patients (De Ferrari et al. 2015). However, high-risk patients need a 
combination of medical therapy and interventional surgery to achieve long periods without 
CPVT symptoms.  
Although the therapy is standardized, no specific treatment for CPVT is known because of 
the lack of understanding of pathomechanism. Disease modeling with induced pluripotent 
stem cells (iPSCs) offers the opportunity for a better understanding of genetic diseases like 
CPVT and may offer a new therapy approach based on genetic correction with Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) / CRISPR associated protein 9 
(Cas9) (Kaminski et al. 2016). 
1.1.5 Genetic background 
CPVT is classified as CPVT1 and CPVT2 corresponding to the genetic background. The 
majority of the CPVT patients are carriers of a mutation in the RyR2 gene with variable 
penetrance, which is classified as CPVT1 (Priori et al. 2002). The minority are CPVT2 
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patients with a recessive mutation in the cardiac calsequestrin isoform 2 gene (CASQ2) (Lahat 
et al. 2001). 
1.1.6 Ryanodine receptor  
Mammalian RyR2 is a homotetramer which consists of four monomers. Each monomer 
has 6-10 transmembrane segments, a cytoplasmic domain functioning as scaffold for 
regulatory subunits and a channel domain at the carboxyl terminus (Liu et al. 2002). Four 
monomers are arranged as large transmembrane segments creating the channel pore 
(Leenhardt et al. 2012). The tetramer builds a macromolecular complex with numerous 
regulatory subunits such as calmodulin (CaM), FK506 binding protein known as FKBP12.6 
or calstabin2, protein kinase A (PKA), Ca2+/calmodulin–dependent kinase II (CaMKII), 
protein phosphatase 1 and 2A (PP1/PP2A), phosphodiesterase 4D3 (PDE4D3), junctin, 
triadin and calsequestrin (Wehrens and Marks 2004). 
Three isoforms of the ryanodine receptor are known, which show a tissue-specific 
expression (Rossi and Sorrentino 2002). RyR1 is mainly expressed in skeletal muscles while 
RyR2 is mostly expressed in cardiac muscles (Marks et al. 1989; Nakai et al. 1990; Zorzato 
et al. 1990; Takeshima et al. 1995). RyR3 is expressed in the nervous system and at low 
levels in mammalian striated muscles (Hakamata et al. 1992; Ledbetter et al. 1994; Giannini 
et al. 1995). 
RyR2 is one of the main important channels to regulate the Ca2+ homeostasis in heart 
muscle cells. The channel is localized in the sarcoplasmic reticulum (SR) and responsible 
for the regulation of intracellular Ca2+ concentration. The SR is an intracellular network 
functioning as Ca2+ storage. L-type Ca2+ channels located in the cell membrane regulate 
contraction of CMs. The L-type Ca2+ channel opens through depolarization of the cell 
membrane during an action potential (AP). The Ca2+ influx triggers opening of RyR2. The 
release of Ca2+ from the SR leads to increasing levels of Ca2+ in the cytoplasm. This 
mechanism is called calcium-induced calcium release (CICR) (Fabiato 1983). 
Myocardial contraction is induced by high intracellular Ca2+ concentrations. Most of the 
Ca2+ surplus is assimilated by the SR Ca2+ adenosine triphosphatase (SERCA) into the SR. 
The remaining Ca2+ is ejected from the cell by the Na+/ Ca2+ exchanger (NCX) to balance 
the Ca2+ entered with the Ca2+ influx (ICa.). The Ca
2+ handling is crucial for the contraction 
of cardiac myocytes and its dysfunctions can lead to severe cardiac diseases such as CPVT.  
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1.1.7 Pathophysiology of CPVT 
At least 50% of CPVT patients carry mutations in the RyR2 gene. The majority of the 
mutations are single base pair (bp) polymorphisms. The mutations are classified in clusters 
in four different hot spot regions of the coding sequence: Domain I (a.a. 77-466), II (a.a. 
2246-2534), III ( a.a. 3778-4201) and IV (a.a. 4497-4959) (Priori and Chen 2011, Marks et 
al. 2002). 10% of reported cases carry a causative RyR2 mutation, which is not located in 
these four domains. The channel function is depending on the domain-domain interaction. 
Defects in a certain domain can interrupt the intermolecular interaction of binding partners 
leading to different phenotypes of the disease. 
The following three hypotheses describe the current stand of research for the 
pathophysiology of CPVT1.  
Hypothesis I: The RyR2 mutation leads to an increased sensitivity to intraluminal Ca2+ and 
a reduced threshold for store overload-induced calcium release (SOICR) resulting in an 
earlier Ca2+ release from the SR during stimulation by catecholamine or stress. The large SR 
Ca2+ spillover can cause delayed after depolarization (DAD) and triggered arrhythmia. The 
increased SOICR is caused by increased sensitivity of RyR2 to luminal Ca2+ (Jiang et al. 
2004) (Figure1).  
 
Figure 1: The mechanisms of CICR and SOICR are schematically shown (modified according to Jiang et al. 
2004). CICR is induced by Ca2+ influx through the L-type channel opening when an AP occurs, which depolarizes the 
cell membrane at rest. The Ca2+ binds to RyR2. The binding causes an activation of RyR2, which leads to Ca2+ release 
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from the SR into the cytosol. The significant increase in cytosolic Ca2+ causes the activation of muscle contraction. 
During stress or the stimulation of the sarcolema by catecholamines, PKA gets activated and binds to phospholamban 
(PLB), a key negative regulator for SERCA2a activity. PLB phosphorylation by PKA releases its inhibition to SERCA2a 
activity, resulting in elevated SR Ca2+ uptake. The concentration of SR free Ca2+ gets increased and causes Ca2+ spillover 
from the SR through RyR2 into the cytosol. The threshold for the SOICR is decreased in CPVT patients by the RyR2 
mutation. This leads to earlier Ca2+ spillover in CPVT patients causing DADs and triggering arrhythmia. 
Hypothesis II: RyR2 mutation causes disruption of FKBP12.6 binding to RyR2. FKBP12.6 
binding stabilizes the closed state of RyR2 during diastole. The binding affinity of 
FKBP12.6 for RyR2 is reduced by the mutation of the RyR2 protein. This leads to 
abnormal Ca2+ leak from the SR, especially during diastole under basal and exhibited 
conditions by PKA phosphorylation of RyR2 (Figure 2). 
 
Figure 2: Schema of reduced binding affinity of FKBP12.6 for mutant RyR2 (modified according to Liu et al. 
2009). The binding affinity of FKBP12.6 for RyR2 is reduced by RyR2 mutation causing the destabilization of the closed 
state of RyR2 in CPVT patients compared to normal RyR2 and phosphorylation of RyR2 by PKA induced through stress 
or catecholamines results in the dissociation of FKBP12.6 from RyR2. These lead to abnormal Ca2+ leak from the SR 
during diastole. .  
Hypothesis III: RyR2 mutation causes disruption of domain-domain interactions. The 
interaction between the N-terminal and the central domain is disrupted through the 
mutated RyR2 protein (Oda et al. 2005; Dobrev et al. 2012). It causes a destabilized closed 
state of RyR2 especially under conditions of stress or the impact of catecholamines because 
the function of an on/off switch of the interaction between the domains is disrupted. This 
leads to an increase in the RyR2 sensitivity to cytoplasmic Ca2+ thereby causing diastolic 
Ca2+ leak which induces DADs and arrhythmias (Laver et al. 2007) ( Figure 3). 
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Figure 3: Scheme of disrupted domain-domain interaction of mutant RyR2 (modified according to Dobrev et 
al. 2012). Besides the FKBP12.6 binding affinity, a proper interaction between the amino terminal domain (green) and a 
central domain (red) of RyR2 is necessary for a normal function of RyR2. The domain interaction functions as an on/off 
switch between open and closed states of the channel. CPVT causes a domain unzipping, destabilizing the closed state of 
RyR2. A diastolic Ca2+ leak from the SR leads to DADs. 
For a better understanding of the pathophysiology, iPSC models enable the possibility to 
examine CPVT patient-derived CMs in vitro to prove and develop theoretical concepts. 
Proof of concept offers the opportunity to find new therapy targets by the understanding 
of the different pathophysiology hypothesis and molecular pathways.  
1.2 Induced pluripotent stem cells  
In 2006, Takahashi and Yamanaka published their astonishing paper about reprogramming 
mouse embryonic or adult fibroblasts to iPSCs by introducing four transcription factors, 
octamer-binding transcription factor (Oct)3/4, sex determining region Y-box 2 (Sox2), 
cellular-Myc (c-Myc) and Kruppel-like factor 4 (Klf4). These cells showed the morphology 
and growth potential of embryonic stem cells (ESCs) and expressed ESC-specific marker 
genes (Takahashi and Yamanaka 2006). The same group created the first human iPSC 
(hiPSC) line with the same transcription factors (Takahashi et al. 2007).  
Yu and her group from James A. Thomson’s lab used a different gene combination: OCT4, 
SOX2, NANOG and LIN28 (Yu et al. 2007).  
To avoid destroying functional genes or activating oncogenes, the Sendai virus (SeV), a 
ribonucleic acid (RNA) virus, was used instead of the former method using lentivirus 
insertion containing the four transcription factors. The SeV has a completely RNA-based 
reproductive cycle (Fusaki et al. 2009).  
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Synthetically modified messenger RNA (mRNA) can also be used to generate RNA-
induced pluripotent stem cells as well (Warren et al. 2010). 
The biggest advantage of DNA-free methods is the prevention of uncontrollable insertions 
of transcription factors in the cell and viral integration inside the chromosomes leading to 
unwanted mutagenesis. 
1.2.1 Differentiation to CMs 
Patient-specific CMs are the foundation for CPVT disease models. The discovery of 
Takahashi and Yamaka to reprogram somatic cells to iPSCs was the main step for the 
establishment of patient-specific disease models. The knowledge about cardiogenesis 
enables the opportunity to differentiate iPSCs to CMs. By this way, the CMs have the same 
genetic information and characteristics like the patients in vivo tissue. 
The differentiation is based on modulating the embryonic developmental signals 
controlling mesoderm induction like activin/NODAL, bone morphogenetic protein (BMP) 
signaling, Wnt and fibroblast growth factor (FGF) and inhibition of Wnt, BMP and TFGβ 
pathways for cardiac specification (Laflamme et al. 2007; Burridge et al. 2011; Kattman et 
al. 2011; Willems et al. 2012; Burridge et al. 2014). 
The modulation of the Wnt pathway during cardiogenesis is crucial for the CM 
differentiation. By temporary modulation of the canonical Wnt/β-Catenin-pathway with 
the use of small molecules in vitro differentiation of iPSCs to CMs could be shown (Lian et 
al. 2012) and adapt to cardiac disease modeling. The Wnt pathway is biphasic activated and 
inactivated during cardiogenesis (Naito et al. 2006). Adapted from the physiological 
cardiogenesis Wnt pathway activation is induced by inhibiting glycogen synthase kinase 3 
(GSK3) with CHIR99021 (CHIR) for the first two days of in vitro differentiation. BMP 
signaling is important in the late phase of iPSC differentiation to CMs (Monzen et al. 1999). 
BMP signaling regulates positively the cardiogenesis (Schultheiss et al. 1997). Especially 
BMP2/4 are expressed in the late phase of iPSC differentiation into CMs. Wnt/β-catenin 
signaling suppresses the expression of BMP2/4. To mimic the physiological settings during 
in vitro iPSC differentiation to CMs, the application of small molecules like IWP2 inhibits 
Wnt/β-catenin signaling to induce a high expression of BMP2/4. 
The use of small molecules and growth factors raises the high amount and purity of in vitro 
generated CMs. 
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1.3 Disease modeling 
The iPSC technology offers the possibility to generate patient-specific in vitro disease 
models, which help to understand molecular mechanisms of diseases. It also offers the 
possibility for drug screening and discovery as well as toxicity tests to develop new drugs. 
Patient-specific iPSCs enable the research on human disease models, which could not be 
recapitulated in small animal models. The genome of the iPSC derived disease models is 
the same to the patient, which is a big advantage in comparison to animal disease models 
(Kim et al. 2013).  
Additionally, gene editing in iPSCs provides the opportunity to achieve specific corrections 
of mutations or to create gene knockout cell lines to prove the relation of genetic 
mutations and the correlating phenotype for a better understanding of the genetic and 
disease background (Colman and Dreesen 2009). 
Another big field is the iPSC-based cell therapy like the transfer of in vitro specialized cells 
back to the patient, which is similar to autologous tissue transplantation to avoid immune 
suppression therapy. A Japanese group transplanted graft sheets with retinal pigment 
epithelial cells derived from patient-specific iPSCs to patients with macular degeneration. 
The outcome of the surgery one year after transplantation was significant and the sight of 
the patients was improved (Mandai et al. 2017).  Adaptive scenarios are in the experimental 
phase like cardiac muscle patches and neuronal cell transplantation in patients with spinal 
cord lesions (Sugiura et al. 2016; Assinck et al. 2017).  
To improve the medical treatment, disease modeling is a useful tool. A future perspective is 
an in vitro test with specific drugs for each patient, which could offer a tailor-made 
medication to develop a personalized medicine (Mathur et al. 2015). The in vitro tests enable 
the check for patient-specific drug metabolism and for compatibility of drugs. This can be 
done theoretically for each type of tissue derived from patient-specific iPSCs (Figure 4). 
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Figure 4: Scheme of the possibilities of disease modeling using patient-specific iPSCs (Bellin et al. 2012). 
Somatic cells can be reprogrammed to iPSCs and differentiated to specialized cells in vitro. There are different kinds of 
application for the in vitro differentiated cells. The cells can be used for cell therapy. (A) IPSCs can be used for disease 
modeling for a better understanding of molecular pathomechanisms. (B) Drug screening can be performed with patient-
specific cells for a better determination of the effects to optimize the therapy and to develop new drugs. (C) Toxicity tests 
can be done. Cardiac, neural and liver toxicity tests can be performed in vitro to estimate the patient-specific cellular toxic 
reasons. Drug screening and toxicity tests represent almost a human preclinical trial in a tube. This can lead to a 
simplification of the drug discovery process. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Molecular Cell Biology (Bellin et al. 2012), copyright (2012). License number 4179481218125 
1.3.1 Disease modeling applied to CPVT 
Modeling CPVT via iPSCs helps to understand the molecular mechanisms of the disease. 
Recent studies based on generated iPSC-CMs from different CPVT patients with different 
mutations in corresponding genes showed the typical arrhythmogenic potential of CPVT 
iPSC-CMs compared to control iPSC-CMs. For example, Itzhaki’s group generated iPSC-
CMs containing a heterozygous mutation in RyR2 (p.M4109R), Fatima’s group a 
heterozygous mutation in RyR2 (p.F2483I) and Novak’s group an autosomal recessive 
mutation in CASQ2 (p.D307H) (Fatima et al. 2011; Novak et al. 2012). The groups 
demonstrated almost similar results. There were no differences in baseline AP properties, 
but huge differences of the arrhythmogenic potential between control iPSC-CMs and 
CPVT iPSC-CMs (Itzhaki et al. 2012).  
Chemicals like forskolin, an adenylate cyclase activator, or isoproterenol, a catecholamine, 
were used to stimulate CMs. The stimulation caused a significant higher development of 
DADs in CPVT iPSC-CMs compared to control iPSC-CMs. In the next step, thapsigargin 
was used to block SERCA and an elimination of DADs in CPVT iPSC-CMs was shown 
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(Itzhaki et al. 2012). Based on this, the hypothesis was confirmed that the depletion of 
intracellular Ca2+ decreases the incidence of DADs in CPVT iPSC-CMs (Fatima et al. 2011; 
Itzhaki et al. 2012; Novak et al. 2012). In addition, Novak’s group showed differences 
between intracellular Ca2+ abnormalities of CPVT1 and CPVT2 CMs and showed that both 
CPVT1 and CPVT2 iPSC-CMs are less mature compared to the control group (Novak et 
al. 2015). 
One of the future targets would be the creation of an analogous stem cell model of CPVT 
like the Long QT models published by Bellin et al in 2013. A specific correction of the 
N996I KCNH2 mutation in long-QT syndrome (LQTS) to elucidate the effect of the 
specific mutant allele and to act as a proof-of-principle for gene therapy was done (Bellin et 
al. 2013). The group showed that the c.A2987T KCNH2 mutation is the primary cause of 
the LQTS phenotype. The same principle of investigation needs to be done with a CPVT 
model to understand the pathogenic mechanism underlying specific disease phenotypes. 
1.3.2 CRISPR/Cas9 systems 
CRISPR/Cas9 systems are genome engineering tools for precise targeting of 
deoxyribonucleic acid (DNA) regions (Jinek et al. 2012).  
CRISPR systems were first discovered as an adaptive immune system in bacteria to fight 
against viral DNA, plasmids or foreign RNA (Garneau et al. 2010). It is able to destroy 
RNA and DNA if they get re-infected. Three types of CRISPR loci are known, which 
acquire spacers from foreign DNA or RNA elements (Barrangou and Marraffini 2014). 
During the process of CRISPR adaptation spacers get integrated into the bacterial genome 
usually in the CRISPR locus, which contains partially palindromic DNA repeats. The loci 
rotate with repeated elements called CRISPR elements. CRISPR repeat RNA (crRNA) is 
the result of transcription and processing of the loci information. The crRNA guides 
nucleases for sequence-specific cleavage of complementary sequences. The combination of 
adaption of foreign genetic material, biogenesis of crRNA and targeting foreign DNA leads 
to a CRISPR-based adaptive immune system (Grissa et al. 2007; Karginov and Hannon 
2010). 
The accurate targeting by type I and II CRISPR systems is supported by protospacers 
assisted by system-specific CRISPR motifs called protospacer adjacent motifs (PAM) 
(Deveau et al. 2008). These are sequences in exogenous nucleic acid elements 
corresponding to CRISPR spacers. PAMs are necessary to separate the foreign DNA from 
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the host genome (Yusa et al. 2011). Invading sequences carrying a PAM get targeted for 
destruction. The PAMs are usually 2 to 5 highly conserved nucleotides. The location of the 
PAM depends on the CRISPR system. In Type I systems it is located on the 5’ end and in 
Type II systems mostly on the 3’ end. 
Type IIA CRISPR systems are usually adapted to genomic engineering tools. The 
advantage of type II systems is the smaller number of Cas proteins. A single Cas9 protein is 
responsible in type IIA systems adapted from Streptococcus pyogenes to form the 
CRISPR-ribonucleoprotein (RPN) complex and for DNA cleavage with the support of a 
recognition lobe and a nuclease lobe. Cas9 interacts with the RNA-DNA duplex, which is 
responsible for the specificity of the target sequence. To simplify the genomic engineering 
tool one single-chain hybrid RNA contains the features of the crRNA duplex and the 
transactivating RNA (tracrRNA) (Jinek et al. 2012). The PAM-proximal region is 
responsible for the high sequence specificity. Mismatches between the first 12 nucleotides 
of the guide RNA (gRNA) and the DNA target are not tolerated. The most common 
PAM-motif is 5’ NGG 3’ resulting from systems based on S. pyogenes.  
CRISPR/Cas9 is a RNA-guided DNA endonuclease system. Cas9 is a CRISPR associated 
endonuclease which forms a complex with two RNA species. The two RNAs function as 
guide sequences, which lead the complex to form base pairs with the DNA target. The 
RNA complex contains a tracrRNA and a crRNA and is engineered as a single guide RNA 
(sgRNA) (Figure 5).  
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Figure 5: Scheme of Cas9 endonuclease to trigger DNA cleavage (Shui et al. 2016). The binding of Cas9 protein 
and the gRNA leads to a conformational change, which enables the gRNA to look for DNA substrate. The Recognition 
lobe (REC) of Cas9 scans for PAM in the genome. The PAM recognition induces a local unwinding of the dsDNA 5’ to 
the PAM region. The unwound DNA is stabilized by protein ssDNA interaction. The base pairing between the ssDNA 
portion and the gRNA extends the ssDNA loop. If a critical loop size is reached Cas9 gets activated to make a double-
strand cut. Cas9 remains bound to the DNA substrate. If base pairing between gRNA and ssDNA is blocked by 
mismatches the ssDNA loop collapses and leads to a release of the Cas9 protein. Reprinted by permission from Hindawi 
Publishers Ltd:  Stem Cells International (Shui et al. 2016), copyright (2016). Creative Commons Attribution 4.0 
International Public License 
The attachment of the complex encourages Cas9 to introduce a site-specific DNA double-
strand break (DSB) by two endonuclease domains. The HNH domain cleaves the 
complementary DNA strand thereby forming a duplex with the sgRNA. The RuvC-like 
domain cleaves the non-complementary DNA strand.  
The design of the sgRNA is the most important part for a successful genomic 
manipulation. To target the wanted DNA sequence a PAM sequence on the DNA needs to 
be present and a 20 base pair (bp) sequence next to the wanted DSB is necessary for a 
successful binding of the CRISPR/Cas9 complex with the DNA. After introduction of the 
targeted DSB the DNA repair mechanisms are used for genetic manipulation. Gene 
knockouts can be forced by the introduction of small deletion or insertion mutations via 
non-homologous end joining (NHEJ). A targeted genetic correction or manipulation is 
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done by insertion of extra sequences via homology-directed repair (HDR) pathway (Sander 
and Joung 2014). 
The CRISPR/Cas9 technology provides an affordable tool for genetic manipulation in 
comparison to zink-finger-nucleases (ZFN) or transcription activator-like effector 
nucleases (TALENs), which have significantly higher costs.  
CRISPR/Cas9 offers the possibility for broad applications, for example as a tool for 
disease modeling in iPSCs and other model organisms. It is possible to correct point 
mutations to confirm if the mutation is responsible for the disease phenotype.  
An American group established a disease model for cystic fibrosis. A genetic correction 
was done on iPSC level with CRISPR/Cas9. The group showed that the homozygous 
deletion of F508 in the cystic fibrosis transmembrane conductance regulator (CFTR) 
caused the disease phenotype. The corrected iPSCs were differentiated into mature airway 
epithelial cells and had a normal CFTR expression and function (Firth et al. 2015).  
Another interesting field is the development of in vitro knockout models in hiPSCs for a 
better understanding of disease and cell adaption mechanisms (Chen et al. 2015). 
1.4 Aims of  this thesis 
The thesis is part of a SFB 1002 project. The project aims to establish in vitro cell culture 
systems using patient-specific iPSCs as the foundation of disease models. IPSCs were 
generated from six CPVT patients with heterozygous missense mutations (R420W, 
A2254V, E4076K and H4742Y) in four different domains of the RyR2 gene. The patient-
specific iPSCs were generated from somatic cells. The generated hiPSCs were tested for 
pluripotency. Subsequently hiPSCs were differentiated to CMs and characterized. Cell 
biological, electrophysiological and phenotypic comparison of CMs was performed. The 
CMs were treated with different anti-arrhythmic drugs and new drugs were tested in vitro. 
This data was obtained in the Prof. Guan-Schmidt’s lab and this thesis should amend the 
following aspects:  
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(1) In the first step of the thesis, iPSC lines generated from a CPVT patient carrying the 
RyR2 mutation E4076K are characterized for their pluripotency on mRNA and protein 
level using reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence 
staining and alkaline phosphatase staining.  
(2) Patient-specific CPVT iPSCs carrying the mutation A2254V are used for genetic 
manipulations by CRISPR/Cas9.  
The presumption is that the disease phenotype of CMs derived from CPVT-iPSCs is 
mutation-specific and not based on the genetic difference between CPVT patients and 
control individuals.  
To prove this concept the CRISPR/Cas9 technology is used to insert a wild type gene 
sequence in the genome to correct the point mutation in RyR2 in the CPVT-iPSCs. In 
addition, the technology is used to create a RyR2 knockout model. 
(3) The CRISPR/Cas9 targeted iPSCs are characterized for their pluripotency on gene 
expression level. The cells are differentiated to CMs and further investigation like 
electrophysiological analysis, Ca2+-confocal analysis and molecular genetic investigations 
will be done. The data will be compared with the original data of the original CPVT-iPSC-
CMs. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Devices 
Table 1: List of devices 
Device Name Supplier 
Cell culture 
Centrifuge 
Multifuge X3R Refrigerated 
Centrifuge 
Thermo Fisher Scientific, 
Heraeus 
Counting chamber Neubauer improved Marienfeld 
Electroporator NucleofectorTM 2b Device Lonza 
Fluorescence-activated cell 
sorting (FACS) cell sorter 
BD FACSAriaTM II sorter BD Biosciences 
Incubator BBD6620 Heraeus Instruments 
Laminar airflow cabinet MSC-Advantage series Thermo Fisher Scientific 
Light-optical microscope Axiovert 4CFL Carl Zeiss 
Pipette Reference, Research plus Eppendorf 
Pipettor Accu-jet pro Brand 
Molecular biology 
Electrophoresis 
Horizontal electrophoresis 
system 
Bio-Rad 
Gel documentation MultiImage Light Cabinet 
Alpha Innotech 
Corporation 
Photometer Biophotometer Plus Eppendorf 
Power supply Power Pac 3000 Bio-Rad 
Tabletop centrifuge Microcentrifuge Eppendorf 
Thermocycler Thermocycler 48 SensoQuest 
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2.1.2 Consumables 
Table 2: List of consumables 
Item Supplier Item number 
Cell culture 
0.5ml Eppendorf container Eppendorf # 4005233 
0.5ml Eppendorf container (brown) Eppendorf # 0030120.155 
1.5ml Eppendorf container Eppendorf # 4004646 
2ml Eppendorf container Eppendorf # 4003961 
15ml reaction tube Eppendorf # 62.554.002 
50ml reaction tube Eppendorf # 62.547.004 
24-Well cell culture plate Eppendorf # 0030722116 
48-Well cell culture plate Eppendorf # 0030723112 
96-Well cell culture plate Eppendorf # 0030730119 
Cover glass, 25mm, round Langenbrinck # 01-0025/2 
Object plate, SuperFrost Ultra Plus Menzel # J3800AMNZ 
Steriflip 50ml Merck Millipore # SCGP00525 
Sterifilter Millex-GS Merck Millipore # GLGS0250S 
Object plate Nunc # 177380 
Cover glass, 22mm, round Omnilab # 5161066 
5ml Serological pipette Sarstedt # 86.1253.025 
10ml Serological pipette Sarstedt # 86.1254.025 
25ml Serological pipette Sarstedt # 86.1685.001 
Cell scraper Sarstedt # 83.1830 
0.1-10μl Pipette tip Starlab # S1111-3700 –c 
S1111-3700-c  
 
10-100μl Pipette tip Starlab # S1112-1720 
S1112-1720-c  
100-1000μl Pipette tip Starlab # S1111-1706 
S1111-1706-c  
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6cm Cell culture dish Starlab # CC7682-3359 
6-Well cell culture plate Thermo Fisher 
Scientific 
# 140675 
12-Well cell culture plate Thermo Fisher 
Scientific 
# 150628 
Molecular biology 
Filtertips 0.1-10μl Starlab # S1120-3810 
S1120-3810-c 
Filtertips 10-100μl Starlab # S1122-1830 
S1122-1830-c 
Filtertips 100-1000μl Starlab # S1120-1840 
S1120-1840-c 
PVDF membrane  
Amersham Hybond P – Western blotting 
membranes 
Sigma-Aldrich #GE10600023  
UVette® Eppendorf # 0030106318 
Whatman gel blotting paper  
Grade GB003 
Sigma-Aldrich  #WHA10426890  
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2.1.4 Chemicals, solutions and kits 
Table 3: List of chemicals, solutions and kits 
Components Supplier Item number 
Cell culture 
0.05% Trypsin- EDTA Life Technologies™ # 25300-054 
0.25% Trypsin-EDTA Life Technologies™ # 25200056 
Albumin, human recombinant Sigma-Aldrich # A0237 / A9731 
B27 Supplement with Insulin Life Technologies™ # 17504044 
CHIR99021 Millipore # 361559 
Collagenase B Worthington 
Biochemical 
# CLS-AFB 
Collagenase IV Worthington 
Biochemical 
# CLS-4 
Dimethylsulfoxide (DMSO) Sigma-Aldrich  # D2650 
DMEM/F-12 Life Technologies™ # 31331028 
Dulbeccó’s phosphate buffered saline 
(DPBS) 
Life Technologies™ # 14190169 
Dulbecco’s modified Eagle medium 
(DMEM) 
Life Technologies™ # 11960044 
Essential 8 (E8) Basal Medium Life Technologies™ # A1516901 
Essential 8 Supplement Life Technologies™ # A1517001 
Ethanol absolute Th. Geyer # 1025490 
Ethylenediaminetetraacetic acid 
(EDTA) 
Carl Roth® # 8040 
Fetal Bovine Serum (FBS) Sigma-Aldrich # F7524 
Gelatin Sigma-Aldrich # 48720 
Geltrex (Growth Factor Reduced) Life Technologies™ # A1413302 
HEPES Buffer (pH 7.0-7.6) Sigma-Aldrich # H0887 
Hydrochloric acid 37% Merck # 1025571 
Iscove’s modified Dulbecco’s medium 
(IMDM) 
Life Technologies™ # 12440053 
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IWP2 Millipore # 681671 
Knockout serum (K.O. Serum) Life Technologies™ # 10828-028 
L-Ascorbic-Acid 2-Phosphate Sigma-Aldrich # A8960 
Methanol J.T. Baker # 8402 
Monothioglycerol (MTG) Sigma-Aldrich # M6145-25ML 
Non-essential Amino Acid (NEAA) Gibco # 11140035 
Penicillin/Streptomycin (P/S) Life Technologies™ # 15140122 
Pro Survival Factor DDD00033325 Millipore # 529659 
RPMI 1640 with HEPES with 
GlutaMax 
Life Technologies™ # 72400021 
RPMI 1640 without HEPES without 
Glucose 
Life Technologies™ # 11879020 
Thiazovivin (TZV) Millipore # 420220 
Versene Solution (0.48mM EDTA) Life Technologies™ # 15040066 
Molecular biology 
5x Green GoTaq® Reaction Buffer Promega # M791A 
6X DNA Loading Dye Thermo Fisher 
Scientific 
# R0611 
Agarose, peq Gold universal agarose Peqlab # 35-1020 
Amaxa™ Human Stem Cell 
Nucleofector™ Kit 2 (25 RCT) 
Lonza # VPH-5022 
Ammonium persulfate (APS) Roth #9178 
Beta-Mercaptoethanol (β-ME) Sigma-Aldrich # M3148 
cOmplete Roche #04693132001 
Dithiothreitol (DTT) Roth #6908 
dNTP Mix Bioline # BIO-39053 
EndoFree Plasmid Maxi Kit (10) Quiagen # 12362 
GeneRuler 100 bp Plus DNA Ladder Thermo Fisher 
Scientific 
# SM0241 
 
Genomic Cleavage Detection Kit GeneArt®  # A24372 
GoTaq® DNA Polymerase Promega # M300B 
GoTaq® G2 DNA Polymerase Promega # M7841 
2  29 
 
 
 
IGEPAL CA-630 Sigma-Aldrich #I3021 
Isopropanol Merck Millipore #109634 
Loading buffer Applichem # A3481 
Magnesium chloride, 25mM Applichem # A1036 
Maxwell® 16 Cell DNA Purification Kit Promega # AS1020 
Midori Green Advance (1 ml) Nippon Genetics 
Europe GmbH 
# MG04 
MuLV Reverse transcriptase (50 U/μl) Life Technologies™ # N8080018 
Non-fat dry milk Roth #T145 
Nuclease free water Life Technologies™ # 1408217 
Oligo d(T)16 Primer Life Technologies™ # N8080128 
PCR Buffer II 10x Life Technologies™ # N8080006 
PhosStop Roche #04906837001 
QIAquick Gel Extraction Kit (50) Quiagen # 28704 
QuickExtract™ DNA Extraction 
Solution 1.0 
BuccalAmp™ # QE09050 
RNase Inhibitor Life Technologies™ # N8080018 
Rotiphorese gel 30 Roth #3029 
Sodium chloride Roth #9265.1 
Sodium dodecyl sulfate (SDS) Roth #2326 
SpeI-HF® restriction enzyme New England 
BioLabs® 
# R3133S 
SV Total RNA isolations kit Promega # Z3100 
SYBR® Green PCR master mix Life Technologies™ # 4309155 
Taq DNA Polymerase with 
ThermoPol® Buffer 
New England 
Biolabs® Inc. 
# M0267S 
Tetramethylethylenediamine (TEMED) Roth #2367 
ThermoPol® Reaction Buffer New England 
Biolabs® Inc. 
# B9004S 
TransIT®-293 Transfection Reagent Mirus # MIR 2700 
Tris Roth #5429 
Tris buffer pure Roth # 1022840 
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UltraPure™ DEPC-Treated Water Life Technologies™ # 750024 
Immunostaining and alkaline phosphatase (ALP) staining 
4’,6-Diamidin-2-phylindol (DAPI) Sigma-Aldrich # D9542 
Alkaline phosphatase, Human Kit 86R Sigma-Aldrich # 1025719 
Bovine serum albumin (BSA), 7.5%, pH 
7.0 
Sigma-Aldrich # A2153 
DAPI Fluoromount-G® Southern Biotech 0100-20 
Giemsa solution Sigma-Aldrich # GS500 
Paraformaldehyde (PFA) Sigma-Aldrich # 158127 
Triton X-100 Sigma-Aldrich # 9002-93-1 
Vectashield Mounting medium Vector Laborites # H-1000 
2.1.5  
2.1.6 Supplements, buffers and solutions 
 
0.25% / 0.05% Trypsin-EDTA 
Defreeze the new bottle and aliquot 6ml and freeze again; store at -20°C 
 
β-Mercaptoethanol [100x] 
Dilute 7μl β-ME in 10ml DPBS; store at 4°C, and prepare fresh weekly 
 
Basic fibroblast growth factor (bFGF)  
Stock solution: 100ng/μl 
100μg bFGF diluted in 1ml Tris (5mM); stored at -20°C 
Working solution: 5ng/μl  
Stock solution diluted 1:20 in 0.1% BSA; stored at 4°C 
2  31 
 
 
 
BSA [1%] 
Dilute 1ml BSA (7.5%) in 6.5ml DPBS; store at 4°C 
 
Cell lysis buffer 
20mM Tris-HCl pH 7.4, 200mM NaCl, 20mM NaF, 1% IGEPAL Ca-630, 1mM Na3VO4, 
1mM DTT, 1 tablet of PhosStop for 10ml or 1 tablet cOmplete (EDTA-free) for 20ml; 
freshly prepared 
 
CHIR99021 [12mM] 
Dissolve 5mg in 0.894ml DMSO; store at -80°C 
 
Collagenase B (400 units/ml), IV (400 units/ml) 
Dissolve 400 units in 1ml RPMI 1640; store at 4°C 
 
FBS 
Heat inactivated for 30min at 56°C 
Enhanced luminescence (ECL) solution 
Mix 4ml of Solution SA with 400μl of Solution SB and add 1.2μl 35% H2O2 
Gelatin [0.1%] 
Dissolve 5g gelatin in 5l distilled water; autoclave 
 
Geltrex™ 
Aliquot 2mg and store at -80°C; dilute directly before use in 12ml cold DMEM/F12 
 
IWP2 [5mM] 
Dissolve 10mg in 4.28ml DMSO and incubate for 10 min by 37°C; store at -20°C 
 
MTG [150mM] 
Dilute 13μl in 1ml IMDM and filtrate sterile, prepare fresh daily 
Non-fat dry milk (5% w/v) 
Dissolve 5g non-fat dry milk in 100ml 1 x TBS-T buffer 
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PFA [4%] 
Dissolve 1g paraformaldehyde in 25ml DPBS; store at -80°C 
 
SDS-loading buffer (10% w/v) 
Dissolve 10g SDS in 100ml H20 
 
5x TBE buffer 
54g Tris, 27.5g boric acid, 20ml 0.5M EDTA (pH8.0) and 1l distilled water 
Triton-X 100 [0.1%] 
Dilute 10μl Triton-X 100 in 990μl DPBS, dilute 1:10 in DPBS; store at 4°C 
 
Tyrode’s solution 
NaCl 140 mM, KCl 5.4 mM, CaCl2 1.8 mM, MgCl2 1 mM, HEPES 10 mM, Glucose 10 
mM, pH 7.4  
 
TZV [2mM] 
Dissolve 10mg in 6.8ml DMSO; store at -20°C 
2.1.7 Cell culture medium  
After FACS – E8 Medium 
 40ml  Conditioned Essential 8 Medium 
 40ml  Essential 8 Medium 
 800μl  P/S 
 200μl   bFGF 10ng/µl 
 80μl  TZV 2mM  
 
B27 medium 
 500 ml RPMI 1640 with HEPES  
 1x B27 supplement with insulin  
 
 
Cardio Culture Medium (storage up to 1 month at 4°C) 
 500ml  RPMI 1640 with HEPES with GlutaMax 
 10ml  B27 Supplement with Insulin (thaw at 4°C) 
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Cardio Differentiation Medium (storage for up to 1 month at 4 °C) 
 500ml   RPMI 1640 with HEPES with GlutaMax 
 250mg   Albumin, human recombinant 
 100mg   L-Ascorbic Acid 2-Phosphate, filter to sterilize  
 
Cardio Digestion Medium (storage for up to 2 weeks at 4°C) 
 80ml  Cardio Culture Medium 
 20ml  Fetal Bovine Serum 
 100μl  TZV (2μM final) 
 
Cardio Selection Medium 
 500ml  RPMI 1640-HEPES-GlutaMax 
 2ml   Lactate/HEPES [1M] 
 250mg  Albumin, human recombinant 
 100mg  L-Ascorbic Acid 2-Phosphate 
 
Cryopreservation Medium feeder free 2x (storage for up to 1 week at 4 °C) 
 2ml  DMSO 
 8ml  Essential 8 Medium 
 20μl  2mM TZV 
 
DMEM/F-12 modified 
Sodium pyruvate, GlutaMax, Glucose 4.5g/l supplemented with: 
 10%  FBS 
 1%   P/S 
 
Essential 8 Medium: storage up to 2 weeks at 4 °C 
 500ml  Essential 8 Basal Medium 
 10ml   Essential 8 Supplement (thaw at 4 °C) 
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hES Medium 
 78ml  DMEM/F-12 
 20ml  Knockout serum replacement 
 1ml  NEAA 
 1ml  β-Mercaptoethanol (100x) 
10ng/ml bFGF (freshly added each day) 
 
Iscove-Differentiation Medium 
 500ml  IMDM 
 127ml  FBS, inactivated 
 6.4ml  NEAA 
450μl   MTG 150mM 
Lysogeny broth (LB)-Medium 
5g    Yeast extract 
10g   NaCl 
10g   Trypton 
1000ml  ddH2O pH 7.0, autoclaved 
for agar plates: 1.5% agar was added 
 
Pre-FACS Medium: 
 25ml  Phenol free E8 + supplement 
 25μl  Thiazovivin (2mM) 
 250μl  P/S 
 1.5%   Fetal Bovine Serum 
 50μl  bFGF (working concentration: 10ng/ml)
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2.1.8 Antibodies for immunofluorescence analysis  
Table 4: List of primary antibodies for immunofluorescence analysis 
Primary Antibody Dilution Supplier 
Pluripotency marker 
SOX2 (mouse) 1:50  (+ 0.1% Triton-X) R&D 
OCT4 (goat) 1:40  (+ 0.1% Triton-X) R&D 
LIN28 (goat) 1:300  (+ 0.1% Triton-X) R&D 
NANOG (goat) 1:200 (+ 0.1% Triton-X) R&D 
Tumour-
related 
antigen-1-60 
(TRA-1-60) 
(mouse) 1:200  Abcam 
Stage-specific 
embryonic 
antigen-4 
(SSEA4) 
(mouse) 1:200  Abcam 
Germ layer marker 
Alpha-1-
Fetoprotein 
(AFP) 
(rabbit) 1:100  DAKO 
β3-Tubulin (mouse) 1:2000  Covance 
Alpha-smooth 
muscle actin 
(α-SMA) 
(mouse) 1:3000  Sigma-
Aldrich 
Cardiac marker 
α-Actinin (mouse) 1:1000  Sigma-
Aldrich 
MLC2A (rabbit) 1:200 (+ 0.1% Triton-X) Protein 
tech 
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MLC2V (mouse) 1:200 (+ 0.1% Triton-X) Synaptic 
Systems 
CX43 
(connexin 43) 
(rabbit) 1:1000  Abcam 
RyR2 (mouse) 1:200  Pierce 
antibodies 
 
Table 5: List of secondary antibodies for immunofluorescence analysis 
Secondary Antibody Dilution Supplier 
Alexa488 (donkey α-mouse) 1:1000  Life Technologies 
FITC (donkey α-rabbit) 1:200 Jackson ImmunoResearch 
FITC (goat α-mouse) 1:100 Jackson ImmunoResearch 
Alexa555 (donkey α-goat) 1:1000 Life Technologies
™ 
Cy3 (goat α-mouse) 1:300 Jackson ImmunoResearch 
Cy3 (donkey α-goat) 1:500 Jackson ImmunoResearch 
Alexa647 (donkey α-mouse) 1:300 Life Technologies
™ 
Cy5 (donkey α-mouse) 1:300 Jackson ImmunoResearch 
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2.1.9 Primer sequences for RT-PCR 
Table 6: List of primer sequences for RT-PCR 
Gene  Primer Sequence (5’-3’) 
Frag
ment 
[bp] 
Pluripotency marker 
FOXD3 hu_FOXD3_for GTGAAGCCGCCTTACTCGTAC  353 
hu_FOXD3_rev CCGAAGCTCTGCATCATGAG 
GAPDH 
 
hu_GAPDH_for AGAGGCAGGGATGATGTTCT 258 
hu_GAPDH_rev TCTGCTGATGCCCCCATGTT 
GDF3 hu_GDF3_for TTCGCTTTCTCCCAGACCAAGGTTTC 311 
hu_GDF3_rev TACATCCAGCAGGTTGAAGTGAACAGCACC 
LIN28 hu_LIN28_for AGTAAGCTGCACATGGAAGG 410 
hu_LIN28_rev ATTGTGGCTCAATTCTGTGC 
NANOG hu_NANOG_for AGTCCCAAAGGCAAACAACCCACTTC 164 
hu_NANOG_rev ATCTGCTGGAGGCTGAGGTATTTCTGTCTC 
OCT4 hu_OCT4_for AGTTTGTGCCAGGGTTTTTG 113 
hu_OCT4_rev ACTTCACCTTCCCTCCAACC 
SOX2 hu_SOX2_for ATGCACCGCTACGACGTGA 437 
hu_SOX2_rev CTTTTGCACCCCTCCCATTT 
Germ layer marker 
hAFP hu_AFP_for ACTCCAGTAAACCCTGGTGTTG 255 
hu_AFP_rev GAAATCTGCAATGACAGCCTCA 
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hALB 
(human 
albumin) 
hu_ALB_for CCTTTGGCACAATGAAGTGGGTAACC 355 
hu_ALB_rev CAGCAGTCAGCCATTTCACCATAG 
hα-MHC hu_α-MHC_for GTCATTGCTGAAACCGAGAATG 413 
hu_α-MHC_rev GCAAAGTACTGGATGACACGCT 
hcTNT hu_cTNT_for GACAGAGCGGAAAAGTGGGA 305 
 
hu_cTNT_rev TGAAGGAGGCCAGGCTCTAT 
hSYP hu_SYP_for TGCAGAACAAGTACCGAGAG 297 
hu_SYP_rev CTGTCTCCTTAAACACGAACC 
Human 
Tyrosine 
hydroxylas
e (TH) 
hu_TH_for GCGGTTCATTGGGCGCAGG 215 
hu_TH_rev CAAACACCTTCACAGCTCG 
RyR2_MUT_B marker 
 
CRISPR_R
yR2_MUT
_B 
hu_CRISPR_Ry
R2_MUT_B_for 
ACACTATGGATGGTGTTTAGAA 560 
 
hu_CRISPR_Ry
R2_MUT_B_rev 
AGAACGTTGGTTCTCCTTCC 
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2.1.10 Program parameters for RT-PCR 
Table 7: List of program parameters for RT-PCR 
Gene 
Annealing 
[°C]  
Cycles Gene Annealing 
[°C] 
Cycles 
Pluripotency marker 
FOXD3 61 38 NANOG 64 36 
GAPDH 60 30 OCT4 54 34 
GDF3 54 34 SOX2 60 30 
LIN28 52 38    
Germ layer marker 
hAFP 58 32 hα-MHC 60 40 
hALB 62 35 hSYP 60 37 
hcTNT 56 35 hTH 60 35 
hGAPDH 55 34    
 
2.1.11 Program parameters for DNA-PCR 
Table 8: List of program parameters for DNA-PCR 
Gene 
Annealing 
[°C]  
Cycles 
RYR_2_MUT_B 59 35 
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2.1.12 Cell lines 
Table 9: List of cell lines used in the study 
Name  
Cells of 
Origin 
Mutation 
Human induced pluripotent stem cell lines (generated in Prof. Dr .rer. nat. Guan-Schmidt’s 
laboratory) 
isCPVTb1.6  Skin 
fibroblasts 
A2254V 
   
isCPVTc2.2 Skin 
fibroblasts 
E4076K 
isCPVTc2.3 Skin 
fibroblasts 
E4076K 
HEK-cell line 
Human embryonic kidney 293T cells (HEK293T): 
(University Medical Center Göttingen) 
  
 
2.1.13 Bacterial material  
Table 10: List of bacterial material  
E.coli 
Top10  F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG  
 
Kindly provided by the 
Department of Immunology, 
University Medical Center 
Göttingen, Thermo Fisher 
Scientific  
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2.2 Methods 
All cells were cultivated under humidified air conditions with 5% carbon dioxide (CO2) and 
20% oxygen (O2) at 37°C. All working steps were performed under sterile conditions.  
Human iPSCs provided for this project were reprogrammed with the overexpression of the 
four Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) by use of the CytoTune-iPS 2.0 
Sendai reprogramming kit (Henze 2016). 
2.2.1 Cell culture 
2.2.1.1 Cultivation of iPSCs on feeder layer  
IPSCs were cultivated on mitomycin C-inactivated mouse embryonic fibroblasts (MEFs) as 
feeder layers to keep them in pluripotent state. The medium was changed daily with 
hES+bFGF.  
The cultures were examined before passaging. Differentiated areas were removed. The 
removal was done by suction, picking or manual passaging.  
Collagenase IV was used for passaging. Collagenase IV was diluted to 200 units/ml 
working concentration with DMEM/F-12 and warmed to room temperature (RT). The 
cells were washed once with 3ml DMEM/F-12 and the supernatant was aspirated. The 
cells were incubated in a 6cm dish with 2.5ml Collagenase IV for 5-7 minutes at 37°C. The 
Collagenase IV was aspirated and the cells were rinsed once with 3ml DMEM/F-12. 3ml 
hES+bFGF medium was added to the cells. With the help of a cell scraper grid-like cuts 
across the cell layer were done. The cells were gently scraped and split onto MEFs. The 
ratio was depending on the confluence of the cell layer before, e.g. 80% confluence was 
split in a 1:4 ratio. Each 6cm dish was filled up to a total of 3ml hES+bFGF medium. The 
plates were labeled. The medium got changed daily.  
2.2.1.2 Cultivation of iPSCs in feeder-free culture 
To standardize several steps a lab intern protocol was used according to the publications of 
the working groups of Beers and Chen (Chen et al. 2011; Beers et al. 2012). 
The human iPSCs were cultivated on 6-well culture dishes coated with Geltrex™ in 
Essential 8™ medium as monolayer culture. The medium was changed daily. 
At 90% confluence the cells were passaged onto new culture dishes. The cells were covered 
with Versene Solution (EDTA solution). The supernatant was directly aspirated. The wash 
step was repeated. The cells were covered with Versene solution and incubated around 2-5 
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min depending on the cell colony size. The Versene solution promotes the detachment of 
the cells. EDTA is a complex binder, which binds bivalent magnesium and calcium ions. 
These ions stabilize the cell binding membrane proteins. The supernatant was aspirated. 
The cells were washed to detach with 1ml Essential 8™ Medium. The cells were 
transferred in Essential 8™ Medium with 2μM TZV in cell culture plate coated with 
Geltrex™. TZV is a selective inhibitor of the Serine/Threonine-Kinase and benefits the 
survival of the stem cells after passaging. The cells were passaged each 5-7 days depending 
on the density. 
2.2.1.3 Cryopreservation on Geltrex™ 
Essential 8™ Medium, Cryopreservation Medium and Versene Solution were warmed to 
RT. The medium of hiPSCs at confluence around 70-90% was aspirated. The cells were 
covered with Versene solution. The Versene solution was directly aspirated. After repeating 
the wash step, cells were covered with Versene solution and incubated for 2-5min at RT. 
The supernatant was carefully removed and 1ml per 6-well of Essential 8™ Medium was 
rapidly added to wash the cells. 1ml of Cryopreservation Medium was given dropwise to 
each well. The cell suspension was carefully mixed and 0.5-1ml of the cell suspension was 
transferred to a labeled cryo tube. The cells were frozen at -80°C in an isopropanol freezing 
container for at least 2 hours and transferred to liquid nitrogen for long-term storage.  
2.2.1.4 Thawing of hiPSCs on Geltrex™ 
The culture dishes coated with Geltrex™ and Essential 8™ Medium were warmed to RT. 
The solution was aspirated and Essential 8™ Medium per 6-well was added. The cryo tube 
was taken directly in a 37°C water bath and observed until only a small ice particle was 
floating. 
The cells were transferred dropwise into a 15ml Falcon tube with 10ml Essential™ 
Medium. The cells were mixed carefully and centrifuged at 200 x g for 5 min. The 
supernatant was aspirated. The pellet was resuspended in Essential 8™ Medium and plated 
on plates coated with Geltrex™. 1μl of 2mM TZV per ml medium was added on the first 
day.  
The medium was not changed on the second day. 1ml of fresh Essential 8™ Medium was 
added to the well and 1μl of 2mM TZV per ml medium was added. 
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2.2.1.5 Nucleofection of hiPSCs cultured on Geltrex™ 
The Human Stem Cell Nucleofector Kit 2 was used to transfer the CRISPR – plasmid into 
hiPSCs. The method is based on electroporation. Human stem cells are sensitive to the 
nucleofection treatment. This requires precise and fast working procedures.  
The cells were cultivated to a confluence around 90%. For each nucleofection, cells in two 
6-wells were needed with a total amount of 4 million.  
The cells were pretreated with 1μl/ml 2mM TZV. Geltrex™ coated plates, E8 medium and 
Versene solution were warmed to RT. 82μl human stem cell nucleofector solution (Kit 2) 
and 18μl supplement 1 were mixed in a 1.5ml tube and warmed to 37°C. The Geltrex™ 
solution was aspirated and E8 medium (3ml per 6-well; 2ml per 12-well) was added onto 
the new plates. 1μl/ml 2mM TZV and 1x P/S were added on the first day.   
The medium of the hiPSCs was aspirated and the cells were covered with Versene solution, 
which was directly aspirated without incubation. The wash step was repeated to remove 
Mg2+ and Ca2+. The cells were covered with Versene solution for 4-6min with minimal 
movement. A longer incubation than at normal passaging was needed to obtain very small 
cell colonies or single cells. The solution was carefully aspirated and E8-medium was added 
rapidly. A 1000μl pipette was used to avoid excessive pipetting to keep the cells intact. The 
cell suspension was carefully mixed. The cells of both wells were collected in one 15ml 
Falcon tube filled with 3ml E8 medium. The cells were counted with a Thoma cell 
counting chamber under a light-microscope. 1.5-3 million cells were transferred in a 15ml 
Falcon tube and centrifuged for 3min at 200 x g. During centrifugation 4-5μg DNA 
(CRISPR-plasmid) and 0.6-1μl of the CRISPR-oligo were added to the prepared 
nucleofector mix.  
The supernatant was aspirated and the cells were resuspended in the nucleofector mix. The 
cells were transferred to a nucleofector cuvette and the cuvette was closed with a cap. The 
sample had to cover the bottom of the cuvette without air bubbles. The cuvette was 
inserted into the nucleofector holder and program A-23 was used. The cells were diluted in 
500μl E8 medium and were gently plated onto three 6-wells. Around 0.5-1 million cells per 
6-well were added to the prepared plates. The plates were shacked back and forth and side 
to side and were incubated under standard conditions. 
The medium was changed on the second day and 1μl/ml 2mM TZV was added. The cells 
had to regenerate for 1-2 days before selection.  
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2.2.1.6 FACS of hiPSCs 
Pre-FACS and After-FACS medium was prepared (the mixtures are listed in 2.1.5) and 
warmed to 37°C. 96-well plates coated with Geltrex™ were warmed to 37°C. The old 
medium of nucleofected cells was aspirated and Versene solution was added and directly 
aspirated. The wash step was repeated. Afterwards Versene solution was added and 
incubated for 3-4 min. The Versene solution was aspirated and 300μl of Pre-FACS 
medium was added to each well (max. 4 wells). The cells were carefully resuspended and 
transferred to a common 15ml Falcon tube. A technician of the hematology and oncology 
department of the University of Goettingen did the FACS sorting. Cells with a GFP signal 
were sorted in a 15ml Falcon tube filled with 3ml After-FACS medium. The cell solution 
was carefully transferred to 96-well plates (10.000 cells per 96-well plate). The wells were 
filled up to ¾ with After-FACS medium. The cells were incubated under standard 
conditions. After 2 days half of the old medium was aspirated and After-FACS medium 
was added. The medium was changed every second day. The cells were passaged after two 
weeks to a 48-well plate, after 3 weeks to a 24-well plate, after 4 weeks to a 12-well plate 
and finally to a 6-well plate. The medium was changed after two weeks to E8 medium 
supplemented with 1μl/ml 2mM TZV. DNA was taken from the 12-well plates to do the 
first genetic analysis. 
2.2.1.7 Mass culture for spontaneous differentiation of hiPSCs cultured on feeder layer 
To confirm the potential for differentiation of hiPSCs in the three different germ layers the 
spontaneous differentiation was done. The iPSCs were cultured to a confluency of 90-
100%. The medium was aspirated and the cells were washed once with 3ml DMEM basal 
medium. The cells were treated with 2.5ml 200 U/ml collagenase IV for 5 min at 37°C. 
The collagenase was removed and the cells were rinsed once with 3ml DMEM. 2.5ml 
hES+bFGF medium were added to each dish. The cells were scraped with a cell scraper in 
big clusters. The cells were resuspended and the clusters were transferred from two dishes 
to an uncoated 6cm petri dish. The embryonic bodies (EBs) were forming in suspension. 
After 24 hours the medium was changed to Iscove-Diff medium and was changed every 2 
days until day 8. The medium change was done following a specific procedure: The EBs 
were collected in suspension and placed in a 15ml falcon for 5 min until the EBs were 
settled at the bottom of the tube. The supernatant was aspirated and fresh Iscove-Diff 
medium was added. The suspension was transferred to a new petri dish.  
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A 6cm dish for pellet collection, two 6cm dishes with 4 coverslips each for immunostaining 
at d8+5, d8+25 and one 24-well tissue culture plate for differentiation efficiency were 
coated with 0.1% gelatin and stored at 4°C overnight. The EBs were prepared for pellet 
collection at day 8. The medium containing the EBs was collected in a 15ml Falcon tube 
and centrifuged at 200 x g for 3 min. The supernatant was aspirated. The pellet was 
resuspended in 1ml PBS. The suspension was transferred to a 1.5ml Epi and centrifuged at 
13.000 rounds per minute (rpm) for 1min. The supernatant was aspirated and the pellet was 
snap-frozen in liquid nitrogen. The samples were stored at -80°C for extended periods. 
Two samples were taken. The rest of the EBs were used for plating. The gelatin was 
removed. 30 EBs in 4ml Iscove-Diff medium were plated on a 6cm dish. One EB was 
plated in each well with 500μl Iscove-Diff medium of the 24-well plate. The EBs were 
cultured in Iscove-Diff medium for another 25 days. The medium was changed every 2-3 
days. On day d8+25 two pellets were taken. The medium was aspirated from the dish and 
washed once with 3ml PBS. The PBS was aspirated and 1ml PBS was added to the dish. 
The cells were carefully scraped in the PBS suspension and transferred to a 1.5ml Epi. The 
suspension was centrifuged at 13.000 rpm for 1 min. The supernatant was aspirated and 
snap-frozen in liquid nitrogen. The samples were stored at -80°C for extended periods.  
The efficiency counting for the spontaneous differentiation was done at d8+5, d8+10, 
d8+17 and d8+25. The beating areas in the 24-well plate were counted under the 
microscope. Three experiments should be done for each cell line.  
2.2.1.8 Cardiac differentiation of iPSCs 
The cardiac differentiation of hiPSCs was done according to the protocols of Lian and 
Burridge to obtain hiPSC-CMs (Lian et al. 2012; Lian et al. 2013; Burridge et al. 2014). 
Modulation of the canonical Wnt-signaling pathway effects the development of hiPSCs to 
mesodermal cells and cardiac progenitor cells (Lian et al. 2013; Burridge et al. 2014).  
At a confluence of 80-100% hiPSCs were plated on 12-well culture dishes coated with 
Geltrex™ (See hiPSC-passaging). At a confluence around 85-95% the E8 Medium was 
replaced with 2ml Cardio Differentiation Medium per 12-well. 0.42μl of 12mM 
CHIR99021 (CHIR) per ml medium was added to the Cardio Differentiation Medium 
before. CHIR is a GSK3 inhibitor working as a Wnt-signal pathway agonist directing the 
development of hiPSCs to mesodermal cells. 24 hours later the medium is replaced by 2ml 
per 12-well of Cardio Differentiation Medium containing CHIR. 48 hours after the 
initiation of differentiation the medium is replaced by 2ml Cardio Differentiation Medium 
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with inhibitor of Wnt production 2 (IWP2, 5mM). IWP2 is a Wnt antagonist blocking the 
Wnt secretion. This leads to the differentiation of the cells to cardiac progenitor cells. At 
day four the medium was changed to Cardio Differentiation Medium without IWP2. 
Beginning from day eight the medium was changed to Cardio Culture Medium. On day 
eight the first contractile functions of the cardiomyocytes were microscopically observed. 
The medium was changed every 2-3 days to specify the development to cardiac muscle 
cells. 
2.2.1.9 Cardiomyocyte digestion  
Cardio Digestion medium, culture dishes coated with Geltrex™, Versene Solution, 
Collagenase B (400 units per ml RPMI) and 0.25% Trypsin-EDTA were warmed to 37 °C. 
The medium of the selected wells was aspirated and washed once with Versene Solution. 
The cells were covered with 37°C warmed Collagenase B (1ml per 6-well and 0.5ml per 12-
well) and incubated for 1-2h at 37°C. The cell clusters were transferred in suspension in a 
15ml Falcon tube. The cells were centrifuged for 5 min at 200 g. The supernatant was 
carefully aspirated and 1-2ml of 0.25% Trypsin-EDTA was added. The cell suspension was 
incubated for 6-10min at 37°C. Double volume of Cardio Digestion medium was added. 
The cells were centrifuged for 5 min at 200 g. The supernatant was aspirated. The cells were 
resuspended in 1-2ml Cardio Digestion Medium. The cell suspension was mixed carefully 
and a desired amount was plated on Geltrex™ coated plates or glass cover slips. The cells 
were incubated for 20-40min to attach. 2ml Cardio Digestion Medium was added. The 
Cardio Culture Medium was changed every 2-3 days.  
A metabolic selection was done on day 20 by changing the medium to a glucose-free 
medium called Cardio Selection medium for 4-6 days. Glucose was replaced by lactate to 
get a higher amount of cardiomyocytes. The cells were cultivated up to day 90. The 
medium was changed every three to four days. 
2.2.1.10 Passaging and culturing of cardiomyocytes for further analyses (Ca2+and voltage 
imaging and immunostaining) 
The cardiomyocytes were cultivated till day 80 – day 85 and passaged afterwards. The 
passaging was done according to the protocol mentioned in chapter 2.2.1.2. The amount of 
cells was determined to 200000 cardiomyocytes per dish. The cardiomyocytes were 
transferred to coverslips coated with 0.1% gelatin or Geltrex™ in 6-well culture dishes. The 
cardiomyocytes were cultivated for 7-10 days in Cardio Culture Medium. Cardiomyocytes 
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were microscopically observed and morphologically compared to control cardiomyocytes 
before further analysis and staining were conducted. 
2.2.2 Alkaline phosphatase staining 
The verification of the alkaline phosphatase (ALP) activity is a stem cell specific 
characteristic. The ALP staining was performed with the ALP, Human Kit 86R according 
to the manufactures details. The same protocol was used for iPSCs on feeder layer and 
iPSCs in feeder-free culture. The cells were cultivated up to a confluence of 60-70%. The 
cells were washed two times with 3ml PBS. After washing 2ml of fixing solution was added 
and incubated for 30s at RT. The fixing solution was aspirated and the cells were washed 
two times with 1ml-distilled water. 2ml-staining solution was added in each dish/well. The 
cells had to be incubated at 37°C for 15-20min. Afterwards, the cells were washed again 
two times with 1ml distilled water. The cells were air-dried overnight. ALP positive cells 
were colored red and were photographed through a light-microscope with 10x 
magnification.  
2.2.3 Molecular biology 
2.2.3.1 Pellet collection for iPSCs 
The pellet collection was performed in the same procedure for iPSCs on feeder layer and 
iPSCs in feeder-free culture.  
The medium was aspirated from the dish/well. The cells were washed once with 3ml PBS. 
1.5ml PBS was added. The cells were carefully scraped in the PBS suspension by the use of 
a cell scraper and transferred to a 1.5ml Eppendorf tube. The cells were centrifuged at 
13.000 rpm for 1 min. The supernatant was aspirated. The pellet was snap-frozen in liquid 
nitrogen. 
The pellets were stored at -80°C for extended periods. 
2.2.3.2 DNA isolation 
Cell pellets were used for DNA isolation. The DNA isolation was done according to the 
manufactures protocol. Maxwell ® 16 DNA Purification Kit was used to isolate the DNA. 
The first step was modified. Instead of using 0.5ml QuickExtract Solution 150μl were used. 
The remaining steps were performed according to the protocol. The DNA was stored at -
20°C. 
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2.2.3.3 RNA isolation 
Cell pellets were used for RNA isolation. The isolation of the total RNA was done with the 
SV Total RNA Isolation Kit (Promega) according to the manufactures guidelines. The 
RNA concentration was measured with a spectrophotometer. 50 µl of isolated RNA were 
pipetted into a nuclease-free cuvette. The light had to pass through the cuvette 
longitudinally. The ratios of 260/280 and 260/230 were noted. Pure RNA should be 
around ~2.0. If the concentration was too high to be measured by the spectrophotometer, 
the probe was diluted 1:10 with nuclease-free water and measured again. The RNA 
concentration was recorded in ng/µl and adjusted to 50 ng/µl nuclease-free water. The 
RNA probes were stored at -80°C. 
2.2.3.4 Reverse transcription reaction 
To perform further gene expression analysis, messenger RNA (mRNA) was transcribed 
into single-stranded complementary DNA (cDNA). Polymerase chain reaction (PCR) 
amplifies the specific cDNA (Mullis et al. 1992). 
100ng of the RNA probes were used for the reverse transcription reaction. To adapt the 
right amount of RNA probe, the RNA probe was diluted in nuclease free water (H2O) and 
should not exceed the volume of 10.2μl. 9.8μl of reverse transcription mix were added to 
the reaction mixture.  
 
Table 11: List of mixture for the reverse transcription reaction 
Mixture for the reverse transcription reaction   
Reagents Volume [μl]  
10 x PCR Buffer II 2 reverse 
transcription 
-mix 
MgCl2 (25mM) 4 
100mM dNTPs 0.8 
RNase Inhibitor (20U/μl) 1 
Oligo d(T)16 (50μM) 1 
MuL V Reverse Transcriptase (50U/μl) 1 
RNA (100ng) in nuclease-free H2O 10.2  
Total: 20  
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The following program parameters were used for the reverse transcription reaction. 
Table 12: Parameters of reverse transcription reaction program  
The amplified cDNA was stored at -20°C.  
2.2.3.5 Gene expression analysis – PCR 
The cDNA was amplified with specific primers for gene expression analysis. The gene 
specific primer sequences are listed in 2.1.7. The PCR reaction mixture contained 24μl 
PCR-mix and 1μl cDNA. The negative control was a reaction mixture with water instead 
of cDNA. 
Table 13: List of mixture for PCR reaction 
 
The amplification of specific cDNA fragments was done according to the following 
program parameters:  
Time [min] Temperature [°C] 
10 22 
50 42 
10 95 
∞ 4 
Mixture for PCR reaction 
Reagents Volume [μl]  
5x Green Buffer 5 PCR-mix 
10mM dNTPs 1 
Primer forward (10μM) 1 
Primer reward (10μM) 1 
GoTaq Polymerase 0.125 
Nuclease-free H2O 15.875 
cDNA 1  
Total: 25 
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Table 14: Parameters of PCR program  
 
The amount of repeats (X) and the annealing temperature are primer-specific and listed in 
the tables in chapter 2.1.8 and 2.1.9. 
2.2.3.6 Agarose gel electrophoresis 
The agarose gel electrophoresis is a molecular biological method to separate DNA 
fragments inside of an electrical field. The fragments were colored with a nucleic acid 
intercalating dye Midori Green. The colored fragments were detected under ultraviolet 
(UV)-light. The examined gene fragments were visualized and the primer specificity of each 
primer pair was proved.  
An 1.5% agarose gel was made by solving 1.8g agarose in 120ml 1xTBE buffer. The 
solution was heated for three minutes by using a microwave. The solution had to cool 
down to 60°C and 4μl of Midori Green were added. The hardened gel was put in a gel 
electrophoresis chamber filled with 1xTBE buffer. Each pocket was loaded with 12μl of 
the probe. A 100 bp Ladder was used as reference. The gel electrophoresis ran for 30 min 
by 120 V voltage. The bands were detected under UV light.  
2.2.3.7 Immunostaining 
This method offers the possibility to characterize the cells on protein level. The 
confirmation of pluripotency and of the potential for differentiation to the three germ 
layers of stem cells was based on immunofluorescence staining. CMs were characterized on 
protein level with specific cardiac markers.  
 Temperature [°C] Time  
Initial denaturation 95 2 min 
Repeat parameter Amount of repeats: 
X - Denaturation 95 30 sec 
- Annealing X 30 sec 
- Elongation 72 45 sec 
Final elongation 72 10 min  
Break 4 ∞ 
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CMs, stem cells or EBs were passaged on cover slips and fixed inside the well. The medium 
was aspirated. The cells were washed three times with 1 x PBS. Afterwards the cells were 
fixed with 4% PFA for 20min at RT. The cells were washed three times with 1 x PBS and 
incubated in 2ml 1% BSA solution overnight at 4°C. The fixed cells could be stored at 4°C 
for a longer time.  
Immunofluorescence staining is based on the formation of an antigen-antibody complex. A 
secondary antibody is linked with a fluorescent dye. The secondary antibody is able to bind 
the primary antigen-antibody complex.  
The staining was done in a H2O humidified chamber. All incubations were done under the 
exclusion of light. The antibodies used for primary staining of the pluripotency markers 
LIN28, OCT4, SOX2, NANOG and for the cardiac specific proteins MLC2A and MLC2V 
were diluted in 1%BSA and the supplement 0.1% Triton X-100 was added to the solution. 
Triton X-100 is able to lysate and permeable the cell membranes.  
The primary antibody staining began with three times of washing the cells with 1xPBS. 
200μl of primary antibody/1% BSA solution (+0.1% Triton-X) were added and incubated 
overnight at 4°C. The cells were washed again for three times with 1x PBS and the 
secondary antibody/1% BSA solution (+0.1% Triton-X) was added. The cells had to 
incubate for 1h at RT. The cells were washed once again with 1x PBS. Afterwards the 
nuclear staining with 0.4μg/ml DAPI was done for 10 min at RT. The colored cells were 
washed three times with 1x PBS and once with distilled water. The colored cells were 
sealed with Fluoromount-G or Vectashield Mounting medium onto object plates. The 
object plates were stored up to four weeks at 4°C. The pictures were made with a 
fluorescent-microscope.  
Sarah Henze did the explicit immunofluorescence staining of RyR2-KO-CMs for α-actinin 
and RyR2.  
2.2.3.8 Selection of CRISPR-clones 
The selection of CRISPR-clones was done via PCR-screening. The PCR-screening was 
based on homologues recombination. The DNA-PCR was done according to the 
instruction listed in 2.2.3.5. After the PCR 0.5μl of SpeI-HF-restriction enzyme was added 
to the amplified DNA probes. The DNA probes were incubated at 37°C overnight. Gel 
electrophoresis was done afterwards according to the instructions listed in 2.2.3.6. 
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2.2.3.9 Genomic sequencing preparation 
The positive CRISPR-clones after secondary selection were sequenced to confirm the 
genomic manipulation. DNA probes created with the QuickExtract Solution described in 
2.2.3.2 were taken. 12μl DNA-solution was added in a 1.5ml Epi tube together with 3μl of 
the corresponding forward primer. Another 1.5ml Epi tube was filled with 12μl DNA and 
3μl of the corresponding reverse primer. The probes were sent for genomic sequencing to 
the company SeqLab Sequences Laboratories GmbH in Goettingen.  
2.2.3.10 Cultivation of Escheria coli (E. coli) 
For cloning experiments, the E. coli strain Top10 F was used. The E. coli strain was used 
to perform the CRISPR project. The cells were cultivated in LB medium at 37°C and 200 
rpm. The cells were cultivated on solid medium. 1.5% agar was added and the bacteria 
incubated at 37°C. Ampicillin 100μg/ml was added to the medium. 
2.2.3.11 Transformation of competent E.coli bacteria with CRISPR plasmids 
E. coli bacteria were thrown on ice for 5-10min. Afterwards 1μl of CRISPR plasmid 
solution was pipetted into the E.coli solution. The solution was mixed by snapping against 
the tube. The solution was incubated for 20min on ice. The bacteria were heat shocked at 
42°C for 90 sec. Subsequently the bacteria were put on ice for 2 min for recovery. 500μl of 
LB medium were pipetted into the tube and were once pipetted up and down. The mixture 
was incubated for 1 hour at 37°C and 350 rpm to allow recovery of the heat shocked 
bacteria. After incubation 40-200μl of the bacteria were plated on LB-agar containing 
Kanamycin plates. The agar plates were incubated at 37°C overnight. A control 
transformation without CRISPR plasmid was performed to check that the Kanamycin was 
working. No colonies appeared in the control transformation. 
2.2.3.12 Plasmid DNA isolation and purification from E.coli 
E. coli bacteria transformed with CRISPR plasmids were incubated in appropriate volume 
of LB medium at 37°C. Kanamycin was added. A resistance was created through the 
transformation of the CRISPR plasmid. 800μl of the culture were used for a glycerin stock 
(200μl of 99% glycerin and 800μl bacteria culture). The isolation of plasmid DNA was 
done with the Maxwell® 16 DNA Purification Kit according to the manufactures 
instructions.  
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2.2.4 Transfection of HEK293T cells using Mirus TransIT®-293  
For the cleavage assay of CRISPR/Cas9 the CRISPR-B-1/Cas9 plasmid was transfected in 
HEK293T cells using the Mirus TransIT®-293 transfection reagent. The transfection was 
done according to the manufacturer’s protocol to obtain a high efficiency. The transfected 
cells were counted and pellets containing around 1x106 cells were prepared by pooling 2-3 
wells as described in 2.2.3.1 and used for cleavage essay. 
2.2.5 Cleavage assay of CRISPR/Cas9 
To detect the cleaving efficiency of the Cas9 nuclease at the target sequence, a cleavage 
assay of the CRISPR-B-1/Cas9 plasmid was performed. The cleavage assay was done 
according the manufacturer’s instructions. The GeneArt® Genomic Cleavage Detection Kit 
was used. In summary, pellets of the transfected HEK293T cells were resuspended in 50μl 
cell lysis buffer/2μl protein degrader mix and a PCR was performed according to the 
manufacturer’s instructions. 2μl of the PCR product were mixed with detection reaction 
buffer in a total volume of 10μl and the re-annealing reaction was started. In the next step 
the detection enzyme cleaved the PCR-product containing the mismatched DNA and the 
sample was loaded on an agarose gel using Ficoll loading buffer. No dye was used to avoid 
interference with band intensity measurements. The determination of the relative 
proportion of gene modification was done with the Alpha Imager Software. 
2.2.6 Protein expression analysis 
2.2.6.1 Western blot analysis 
The cells were cultivated and probed for the Western blot analysis by myself. Sarah Henze 
performed SDS-polyacrylamide gel electrophoresis and took the images together with her 
probes for the CPVTc2 experiments. 
2.2.6.1.1 Preparation of cell lysates 
For cell lysis, frozen cell pellets were resuspended in 80-100μl cell lysis buffer and 
incubated for 30 min on ice. To remove bigger cell fractions, lysates were centrifuged 
(2,400 x g, 5 min, 4°C). The supernatant was transferred into a new reaction tube. 5μl of 
each sample were diluted in 95μl DPBS for measurements of protein concentrations. The 
protein concentration was quantified using the Pierce BCA protein assay kit according to 
the manufacturer´s instructions with a 96-well photometer at 562nm. The samples were 
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prepared for SDS-PAGE or alternatively stored at –80°C for further use. A total amount 
of 40μg protein lysate was mixed with SDS loading buffer and DPBS in 20μl and 
denatured for 30 min at 37°C before SDS-PAGE analysis. 
2.2.6.1.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
By SDS-PAGE charged proteins are separated according to their molecular weight. The 
separation gel was mixed according to Table 15 and poured between two glass plates 
separated by spacers and fixed with clamps. Solutions for the separation gel were covered 
with a thin layer of isopropanol. The isopropanol was decanted after polymerization. A 
stacking gel was poured on top. A comb was inserted. After polymerization of the stacking 
gel, the whole gel was attached to an electrophoresis chamber, filled with 1x running 
buffer. The samples were loaded together with a prestained molecular weight marker. 
Electrophoresis was performed at constant amperage of 30mA for approximately 2 hours. 
To visualize the separated proteins, the gels were further processed by immunoblotting  
Table 15: Components for separation and stacking gel 
 
2.2.6.1.3 Protein transfer and detection 
Proteins, which were separated by SDS gel electrophoresis, were transferred to 
polyvinylidene difluoride (PVDF) membranes using the Wet/Tank blotting system. Four 
filter papers were batched in 1x transfer buffer. The PVDF membrane was activated 
according to the manufacturer’s instructions. Two filter papers were placed on the black 
site of the holder cassette. The SDS gel was placed above the PVDF membrane and two 
additional filter papers. The protein transfer was cooled with ice during the blotting (400 
mA, 2h). 
3% BSA/TBS-T or non-fat dry milk was used to block the free binding sites on the PVDF 
membrane (60 min, RT). Primary antibodies diluted in 1-3% BSA/TBS-T (4°C, overnight) 
Separation gel 12ml 6% 12% 15% Stacking gel 7.5ml 2 gels 
Rotiphorese gel 30 2ml 4.8ml 6ml  1ml 
4x Tris/SDS pH 8.8 3ml 3ml 3ml 4x Tris/SDS pH 6.8 1.88ml 
ddH20 6.6ml 4.2ml 3ml  4.62ml 
10% APS 48μl  48μl 48μl  37.5μl  
Temed 18μl  18μl  18μl   15μl  
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were used for the immunostaining together with the HRP-conjugated secondary antibodies 
diluted in 1% BSA/TBS-T (60 min, RT). The membrane was washed three times with 
TBS-T during the incubation period. By adding ECL reagents the antigens of interest were 
detected. The results were documented with a chemiluminescence detection system. 
2.2.7 Calcium imaging 
The cells were prepared for calcium imaging by myself. Lukas Cyganek performed the 
confocal measurements and Sarah Henze helped with the analysis. 
For calcium imaging, cells were digested and plated on Geltrex-coated 25mm glass 
coverslips and afterwards incubated in B27 medium 5 to 7 days before the calcium 
recording. At day 86-118 cells were used and washed twice with Tyrode’s solution. In the 
next step cells were incubated for 30 minutes with 5μl fluo-4/AM fluorescent calcium 
indicator and 0.02% [w/v] pluronic F-127 in Tyrode’s solution at 20-22°C. Afterwards the 
cells were washed twice with Tyrode’s solution. The cells were paced by using a recording 
chamber with platinum electrodes in Tyrode’s solution at 20-22°C. The medium was 
changed every 10 minutes. The field stimulation was performed at 0.25Hz (18V, 3ms 
duration) and the calcium recording was performed. LSM 710 confocal microscopy system 
with a 63x 1.4 NA oil objective in line scan mode (512 pixels, 45μm, 1057.7Hz, 20,000 
cycles) exciting at 488nm and collecting emission at 490-540nm was used to capture 
images. The analysis of the intracellular calcium concentration variation was performed 
using ImageJ and Microsoft Excel. The calcium concentration change was analyzed as a 
function of the time. During diastolic phase a defined plot per recording (500ms, 25μm) 
was analyzed by ImageJ Spark Master (settings: 1057.70lps; 0.088μm; Fl. U. 0; criteria 3.3; 
intervals 3).  
2.3 Vote of  the Ethics Committee 
All experiments were done according to the vote of the ethics committee. The application 
number of the vote of ethics committee of the University Clinic Goettingen is 
DK_89_2015. 
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3 Results 
3.1 Characterization of  iPSC lines 
Disease models using iPSCs for CPVT patients with different mutations were established 
in the lab. Skin biopsies were taken from CPVT patients for the generation of iPSCs. The 
iPSCs were generated via SeV transduction containing the Yamanaka factors KLF4, C-
MYC, OCT4 and SOX2 (Fusaki et al. 2009). The CPVT disease models for this project 
were based on iPSCs from CPVT patients b1 and c2, who had a missense mutation 
A2254V or E4076K at different loci, respectively.  
The human iPSC line isCPVTb1.6 was previously characterized in feeder culture conditions 
for the pluripotency after successful reprogramming in the lab and was used for the 
CRISPR experiments. Characterization of iPSCs includes ALP, gene expression and 
protein expression of pluripotency-associated markers and the proof of the differentiation 
potential in all three germ layers. Immunofluorescence staining enables the characterization 
of the cells on protein level. The RT-PCR method as a gene expression analysis allows 
characterization on mRNA level. The proof of ALP activity was done, because of the high 
activity in pluripotent stem cells.  
In this study, the two iPSC lines isCPVTc2.2 and isCPVTc.2.3, which were generated from 
CPVT patient c2, were fully characterized. 
3.1.1 Alkaline phosphatase staining of the human iPSC lines 
ALP is a hydrolase enzyme which shows high activity in undifferentiated ESCs and iPSCs 
(Wobus et al. 1984; Pease et al. 1990; Kim and Wyckoff 1991). The high alkaline 
phosphatase activity was verified as red precipitate in the analyzed iPSC lines isCPVTc2.2 
and isCPVTc2.3 (Figure 6). 
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Figure 6: Alkaline phosphatase staining of the human iPSC lines isCPVTc2.2 and isCPVTc2.3. The figure 
shows ALP staining (10x) of isCPVTc2.2 and isCPVTc2.3 cultured on MEFs. The red staining in all iPSC lines proved 
the high enzymatic activity. The pictures were taken without phase contrast and with automatic white balance. (Scale bar: 
100 μm) 
3.1.2 Proof of the expression of pluripotency-associated marker genes at mRNA 
level 
The analysis of cellular gene expression patterns of the iPSC lines was carried out by the 
use of RT-PCR. As proof of pluripotency the iPSC lines were examined for the expression 
of pluripotent stem cell-specific marker genes. SOX2, OCT4, NANOG, LIN28, GDF3 and 
FOXD3 were used as pluripotency markers (Reubinoff et al. 2000; Hanna et al. 2002; 
Chambers et al. 2003; Richards et al. 2004; Levine and Brivanlou 2006; Zhang and Cui 
2014). Human ESCs were used as positive control. MEFs and patient-specific fibroblasts 
were used as negative controls (Figure 7). 
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Figure 7: Proof of pluripotent stem cell-specific marker gene expression on mRNA level. Gel electrophoresis of 
RT-PCR products are shown. The following marker genes were proved on their expression at mRNA level: SOX2 
(437bp), OCT4 (113bp), NANOG (164bp), LIN28 (410bp), GDF3 (311bp) and FOXD3 (353bp). GAPDH (258bp) was 
used as intern control. The iPSC lines isCPVTc2.1, isCPVTc2.2, isCPVTc2.3 and isCPVTc2.4 were proved. The positive 
control was done with human ESCs. The negative control was done with MEFs and patient-specific skin fibroblasts (Fib 
CPVTc2). The pluripotency-associated markers were detected in all pluripotent stem cell lines. 
The pluripotency factors SOX2, OCT4, NANOG, LIN28, GDF3 and FOXD3 were 
expressed in all iPSC lines analyzed and showed a corresponding expression pattern to 
human ESCs used as positive control. These pluripotency genes were expressed at very low 
levels in their parental fibroblasts. The intern control GAPDH showed in all probes a 
similar intensity. The MEFs used for negative control showed no expression of stem cell 
specific marker genes. 
3.1.3 Proof of the expression of pluripotency-associated markers at protein level 
For demonstrating the pluripotency of iPSCs at protein level immunofluorescence staining 
was performed. The iPSCs were fixed with 4% PFA and stained with antibodies against 
pluripotency-specific proteins OCT4, SOX2, LIN28, NANOG, SSEA4 and tumour-related 
antigen-1-60 (TRA-1-60) and their corresponding secondary antibodies. The cells were 
microscopically examined. OCT4, SOX2 and NANOG are important pluripotency factors, 
which are expressed in the cell nucleus. The antibodies against SSEA4 and TRA-1-60 
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detect antigens at the cell surface of pluripotent stem cells. The LIN28 antibody binds to 
cytoplasmic antigens (Brimble et al. 2007; Schopperle and DeWolf 2007). The nucleus 
staining was done with DAPI, which is detectable with UV light with a wavelength of 
461nm. Figure 8 shows blue nucleus staining with DAPI and the pluripotency markers 
OCT4 SOX2 and NANOG are colored in red. The cytoplasmic marker LIN28 is colored 
in red. The expression of surface markers SSEA4 and TRA-1-60 was proved in the two 
iPSC lines analyzed. The DAPI staining is overlaid with the antibody staining in the figure 
(Figure 8). 
 
Figure 8: Proof of the expression of pluripotency-associated markers at protein level. The immunofluorescence 
staining of pluripotent stem cell-associated markers is shown and also in an overlaid picture with DAPI. The transcription 
factors OCT4, SOX2 and NANOG, the surface markers SSEA4 and TRA-1-60 and the cytoplasmic marker LIN28 are 
expressed in all examined iPSC lines. The pictures were taken with a 20x image enlargement. The protein expression of 
pluripotency-associated markers was proven in both iPSC lines isCPVTc2.2 and isCPVTc2.3. (Scale bar: 100μm) 
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3.1.4 Proof of the iPSC differentiation potential in vitro 
The spontaneous differentiation of human iPSCs was done according to the established 
protocol of the stem cell laboratory at the cardiology and pulmonology department. To 
prove the differentiation potential of iPSCs into all three germ layers ectoderm, mesoderm 
and endoderm, immunofluorescence staining was done for two cell lines. The 
differentiated EBs were fixed with 4% PFA and stained with germ layer-specific antibodies 
and visualized with fluorescence marked secondary antibodies. β3-tubulin, which is a 
neuron-specific isoform of the tubulin, was used as ectodermal marker. The α smooth 
muscle actin (α-SMA) was used as mesodermal marker and the glycoprotein alpha-1-
fetoprotein (AFP) was used as endodermal marker (Pekkanen-Mattila et al. 2010; Martí et 
al. 2013). The expression of the germ layer-specific markers was shown in both iPSC lines 
after differentiation (Figure 9).  
Figure 9: Proof of the expression of germ layer-specific markers at protein level. The figure shows the 
immunofluorescence staining of antibodies specific for three germ layers and also in an overlaid picture with DAPI. 
The following germ layer-specific markers were stained: AFP (endoderm) α-SMA (mesoderm) and β3-tubulin 
(ectoderm). The pictures were taken with a 20x image enlargement. At d8+25 protein markers of the three germ layers 
were proved in both iPSC lines. (Scale bar: 100μm) 
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3.2 CRISPR/Cas9-mediated gene editing of  RyR2 
One patient-specific iPSC line isCPVTb1.6, which contains the mutation A2254V in RyR2, 
was used for the CRISPR/Cas9 mediated genetic-targeting. The missense mutation is 
localized in the genomic sequence expressing the cytosolic part of RyR2. The missense 
mutation A2254V in isCPVTb1.6 was confirmed by sequencing previously.  
3.2.1 CRISPR/Cas9 design 
The combined and customized CRISPR/Cas9 plasmid (Figure 10) was designed and 
generated including the gRNA sequence with a 22bp RyR2-targeting region. The 
CRISPR/Cas9 plasmid contains the gRNA, a Cas9 enzyme and GFP for selection of 
positive transfected cells. Several gRNAs were designed, bioinformatic analysis of off-
target prediction of the gRNAs was performed by Sigma-Aldrich and a gRNA (Crispr1) 
with 2 off-targets at 3 mismatches was used in this study (Figure 11), which gave the lowest 
amount of off-targets and about 34bp away from the mutant site (c.C6761T). The designed 
plasmid CRISPR-B-1/Cas9 was ordered at Sigma-Aldrich (Figure 10).  
 
Figure 10: The combined customized CRISPR-B-1/Cas9 recognizes a specific 22-bp binding site for the 
domain b of RyR2.  
The mutation C>T in exon 44 of RyR2 causes an amino acid change from alanine (GCA) 
to valine (GTA). Additionally, the mutation leads to the generation of a SpeI (ACTAGT) 
restriction site. A single strand oligodeoxynucleotide (ssODN) was designed as a template 
to correct the C>T mutation in RyR2 (Figure 11 and 12). The designed ssODN carried the 
T>C correction and a total of 107 nucleotides of homologous sequence flanking the 
mutation site. The SpeI restriction site should be destroyed after the genetic correction. 
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The mutated restriction site after genetic correction can be further used for a primary 
screening (Figure 11). 
 
Figure 11: CRISPR/Cas9 design for the RyR2 mutation c.C6761T. Crispr1 was designed according the 
binding characteristics of the sgRNA of the CRISPR/Cas9 complex. The sgRNA binds best at a PAM sequence 
and about 34bp away from the mutant site (c.C6761T). The ssODN was designed as a template for the genetic 
correction. The genetic correction causes a destruction of the SpeI restriction enzyme binding site additionally. 
Forward and reverse primers were designed for genomic sequencing flanking the respective 
exon. The fragment defined through the primer contains 560bps. Genomic sequencing was 
used to show the genetic correction or the creation of a knockout model on base level. 
 
Sequence 
ssODN for CRISPR1 5‘-
GCCTCCCCAGCTATGAGAGGTTCAACACCACTGG 
ATGTGGCTGCAGCTTCGGTGATGGATAATA 
ATGAACTAGCATTAGCTCTGCGTGAGCCGG 
ATCTAGAAAAGGT-3’ 
Figure 12: Design of ssODN for CRISPR1 
3.2.2 Cleavage assay  
The CRISPR-B-1/Cas9 cleavage efficacy was tested with a cleavage assay. HEK 293T cells 
were transfected using Mirus TransIT®-293 Transfection Reagent with the CRISPR-B-
1/Cas9 plasmid (Figure 13). The DNA samples of the transfected cells were amplified 
using primers flanking the RyR2 mutation region, used for the cleavage assay to detect 
deletions or insertions (indel) and analyzed on agarose gel.  
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Figure 13: Representative image of HEK293T cells expressing the CRISPR-B-1/Cas9 plasmid including a 
GFP signal. The HEK293T cells were transfected with the CRISPR-B-1/Cas9 plamid using Mirus TransIT®-293 
Transfection Reagent. The GFP signal was detectable after 24-48 hours. (Scale bar: 100 μm) 
The intensity of the digested and undigested bands was quantified. The plasmid CRISPR-
B-1/Cas9 had an estimated cleavage efficiency of 15-20%. The positive control had 
cleavage efficiency around 21-24%. 
3.2.3 Generation of CRISPR-B-1/Cas9-targeted iPSC lines 
Figure 14 shows the strategy for generating CRISPR/Cas9-targeted CPVT-iPSC lines. The 
CRISPR-B-1/Cas9 gene-targeting plasmid and ssODN were introduced by nucleofection 
into isCPVTb1.6 iPSCs to generate CRISPR-B-1/Cas9-targeted hiPSC clones. Different 
methods were used to improve the transfection efficiency. Nucleofection showed the best 
outcome. In the next step transfected cells were sorted via FACS for GFP positive cells. 
Flow cytometry analysis showed that the GFP positive rate of living transfected cells 
ranged around 1-3% (Figure 15). 
 
Figure 14: Strategy for generating CRISPR/Cas9-targeted CPVT-iPSC lines. CRISPR-B-1/Cas9 gene-targeting 
plasmid was introduced into isCPVTb1.6 iPSCs by nucleofection using 2 million cells mixed with 4μg plasmid and 3.3μg 
ssODNs as donor DNA. 24 hours after nucleofection, GFP positive iPSCs were sorted by FACS. 2-7 x 103 cells were 
seeded on each Geltrex coated 96-well plate (1-10 cells per well) in a 1:1 mix of E8 and MEF-conditioned E8 medium 
supplemented with additional bFGF (10 ng/ml), TZV, 1x P/S (first week), which was changed every third day. After 10-
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18 days single colonies were transferred into Geltrex-coated 48-well plates. Confluent cells in 48-well plates were 
transferred onto two wells of 24 well plates for cryopreservation and DNA extraction, respectively. Genomic DNA was 
isolated and analyzed for targeted integration by PCR and SpeI restriction digestion. Negative digested cell clones were 
sequenced. 
 
Figure 15: Example: FACS sorting for GFP positive cells. The CRISPR-B-1/Cas9 gene-targeting plasmid and 
ssODN were introduced by nucleofection into isCPVTb1.6 iPSCs. 24 hours after nucleofection the cell sorting via FACS 
was done according to the intensity of the GFP positive signal. Population P4 matches for GFP positive cells after 
nucleofection. Population P4 was sorted and cultivated for further analysis afterwards. The transfection efficiency of 
iPSCs ranged between 1-3%.  
The primary screening of positive clones for HDR was done by restriction digestion. The 
binding site of the restriction enzyme was destroyed through the genetic correction  
(Figures 11 and 12). 
An edited genome by the CRISPR-B-1/Cas9 in combination with ssODNs for HDR 
should be accompanied with a mutated SpeI restriction site in isCPVTb1.6 patient cell line 
and successfully genome edited iPSC lines should display only one DNA fragment 
compared to two fragments in isCPVTb1.6 iPSC line (Figure 16). 
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Figure 16: Representative PCR and restriction digestion shows positive not-digested CRISPR-targeted clones 
(X2, X4). The CRISPR/Cas9 complex destroyed the restriction site in genomic edited clones. No digested fragments are 
shown after digestion with SpeI in the CRISPR-targeted clones. The other cells show digested fragments after digestion. 
 
In total, 68 GFP positive clones derived from isCPVTb1.6 cell line were expanded and 
screened for correction of mutation via PCR and subsequent restriction enzyme digestion. 
The primary screening showed two targeted clones (X2 and X4). Sequencing of the 
genome of two clones X2 and X4 showed an integration of the ssODNs close to CRISPR-
B-1/Cas9 cleavage site in clone X4 as well as additional deletions in the genome of clone 
X2 and clone X4 (Figure 17).  
Clone Origin ssODN Sequence 
X2 isCPVT b1.6 
CRISPR-Oligo-
b1 
Allele 1:  
5’- 
GCCTCCCCAGCTATGANAGGTTCAACACCMNNGGN
------3’ 
Allele 2:  
5’- GCCTCCCCAGCTATGANAGGTTCAACACC------3’ 
X4 isCPVTb1.6 
CRISPR-Oligo-
b1 
Allele 1:  
5’-GCCTCCCCAGCTATGAGAGGTTCAACACCA----
ATGTGGCTGCAGCTTCGGTGATGGATAATAATGAA
CTAGCATTAGCTCTGCGTGAGCCGGATCTAGAAAA 
GGT-3’ 
Allele 2:  
5’-GCCTCCCCAGCTATGAGAGGTTCAACACCA----
ATGTGGCTGCAGCTTCGGTGATGGATAATAATGAA
CTAGCATTAGCTCTGCGTGAGCCGGATCTAGAAAA
GGT-3’ 
b1.6 
WT 
isCPVT b1.6 - 
Allele 1: Mutation in exon 44 C>T 
5’-
GCCTCCCCAGCTATGAGAGGTTCAACACCACTGGAT
GTGGCTGCAGCTTCGGTGATGGATAATAATGAACT
AGTATTAGCTCTGCGTGAGCCGGATCTAGAAAA 
GGT-3’ 
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Figure 17: Sequencing of CRISPR-B-1/Cas9-targeted clones. Both clones were sequenced to test if the genetic 
correction or the creation of a KO-cell line worked. The clones were preselected by restriction enzyme digestion. Clone 
X4 had a homozygous deletion of 4 bps. 
However, no isogenic corrected isCPVTb1 cell lines were created with CRISPR-B-1/Cas9. 
Instead, iPSC lines with a RyR2 knockout were generated with CRISPR-B-1/Cas9. The 
generated X4 clone of isCPVTb1 iPSCs showed the integration of the ssODNs, but had a 
homozygous nucleotide deletion of 4bps. The deletion caused a reading frameshift with a 
premature stop codon at the a.a. position 2246 in the cytosolic domain of RyR2, which 
causes the loss of the transmembrane domain of the RyR2 receptor. As a result the channel 
pore of the RyR2 is not formed anymore, and the generated isCPVTb1.6_X4 is a cell line 
with complete knockout of RyR2. The isCPVTb1.6_X2 clone showed an analogous 
pattern. The generated X2 clone had several nonsense mutations early before the targeted 
sequence at the a.a. position 2245. The manipulated base sequence caused a reading frame 
shift, which causes the loss of the transmembrane domain of the RyR2 receptor as well as 
in clone X4. It did not show a successful genetic correction of the defined locus.. 
isCPVTb1.6_X2 was not further examined because the cultivation and differentiation 
process to CMs was problematic. Further studies were performed with the 
isCPVTb1.6_X4 cell line. 
To show that the CRSPR-B-1/Cas9-targeted clone (X4) has the similar pluripotent 
characteristics like non-transfected isCPVT1.6 iPSCs, different methods to prove 
pluripotency were used. The pluripotency was proved at mRNA level with RT-PCR and at 
protein level with immunostaining.   
The first step was to show a high ALP activity with alkaline phosphatase staining, which is 
a marker for undifferentiated ESCs and iPSCs (Figure 18). 
Allele 2: 
5’- 
GCCTCCCCAGCTATGAGAGGTTCAACACCACTGGAT
GTGGCTGCAGCTTCGGTGATGGATAATAATGAACT
AGCATTAGCTCTGCGTGAGCCGGATCTAGAAAAGG
T-3’ 
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Figure 18: Alkaline phosphatase staining of the CRISPR-B-1/Cas9-targeted clone X4. The figure shows ALP 
staining (10x) of isCPVTb1.6_X4 cultured on Geltrex. The red staining proved the high enzymatic activity. The picture 
was taken without phase contrast and with automatic white balance. (Scale bar: 100μm) 
The CRISPR-B-1/Cas9-targeted clone X4 was examined for the expression of pluripotent 
stem cell-specific marker genes on mRNA level. SOX2, OCT4, NANOG, LIN28, GDF3 
and FOXD3 were used as pluripotency markers. Human ESCs were used as positive 
control. MEFs were used as negative control. The pluripotency factors SOX2, OCT4, 
NANOG, LIN28, GDF3 and FOXD3 were expressed in the CRISPR-B-1/Cas9-targeted 
clone X4 and showed a corresponding expression pattern similar to its parental cell line 
isCPVTb1.6 and to human ESCs. GAPDH was used as an intern control and showed in all 
probes a similar intensity. No expressions of pluripotent stem cell-specific marker genes 
were shown in MEF cells (Figure 19). 
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Figure 19: Proof of pluripotent stem cell-specific marker gene expression on mRNA level. Gel electrophoretic 
separations of products of RT-PCR are shown. The following marker genes were proved on their expression at mRNA 
level: SOX2 (437bp), OCT4 (113bp), NANOG (164bp), LIN28 (410bp), GDF3 (311bp) and FOXD3 (353bp). GAPDH 
(258bp) was used as internal control. The iPSC line isCPVTb1.6_X4 showed similar expression as isCPVTb1.6. The 
positive control was done with human ESCs. The negative control was done with MEF cells. The pluripotency-associated 
markers were detected in all stem cell lines. 
For demonstrating the pluripotency of the CRISPR-B-1/Cas9-targeted clone X4 at protein 
level immunofluorescences staining was performed according to the standardized protocol. 
The cells were fixed with paraformaldehyde and stained with antibodies against 
pluripotency-specific proteins OCT4, SOX2, LIN28, NANOG, SSEA4 and TRA-1-60 and 
their corresponding secondary antibodies. OCT4, SOX2, LIN 28 and NANOG were 
expressed in the CRISPR-B-1/Cas9-targeted clone X4. The expression of surface markers 
SSEA4 and TRA-1-60 was also proved in the CRISPR-B-1/Cas9 targeted clone X4 (Figure 
20). 
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Figure 20: Proof of the expression of pluripotency-associated marker at protein level. The immunofluorescence 
staining of pluripotent stem cell-associated markers are shown and also in an overlaid picture with DAPI. The 
transcription factors OCT4, SOX2 and NANOG, the surface markers SSEA4 and TRA-1-60 and the cytoplasmic marker 
LIN28 are expressed in the examined stem cell line. The pictures were taken with a 20x image enlargement. The protein 
expression of pluripotency-associated markers was proven in the stem cell line. (Scale bar: 100μm) 
The expression of pluripotency-associated markers was shown at mRNA and protein level. 
The CRISPR-B-1/Cas9-targeted clone X4 showed similar pluripotent characteristics like 
the non-transfected iPSCs. 
After the proof of pluripotency, the CRISPR-B-1/Cas9-targeted clone X4 was 
differentiated into CMs for further analysis. 
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3.3 Cardiac differentiation 
The in vitro differentiation of human iPSCs to cardiomyocytes was performed according to 
established protocols. The canonical Wnt/β-catenin signaling pathway plays a crucial role 
for the differentiation of iPSCs into CMs (Lian et al. 2012; Lian et al. 2013; Burridge et al. 
2014). Figure 21 shows the chronological sequence of the in vitro differentiation protocol.  
 
Figure 21: Scheme of the in vitro differentiation protocol of human iPSCs to cardiomyocytes. The human 
iPSCs were cultivated in E8 medium on Geltrex™ coated plates. After reaching a confluent cell density the mesodermal 
induction was started by adding CHIR [5μM] for 48h. The cardiac induction was accomplished by adding IWP2 [5μM] 
for another 48h. (day =d) 
The isCPVTb1.6 iPSCs and the CRISPR/Cas9-targeted clone X4 were cultivated in E8 
medium on Geltrex™ coated plates to a confluent cell density. The mesodermal induction 
got started by adding CHIR99021 [5μM] for 48h. By adding IWP2 [5μM] for another 48h 
the cardiac induction was accomplished. The cells were cultivated in Cardio Differentiation 
Medium up to day 90, while the majority of the cells show already contractile functions 
from day 8/9 on. A metabolic selection was performed after day 20 by using a glucose-free 
medium for 4-6 days with the addition of lactate to reach a high amount of CMs. The 
maturation of CMs to an adult-similar phenotype was carried out in a longtime culture in 
Cardio Culture Medium up to day 90. CMs were examined on their cell biological and 
functional characteristics. 
First microscopically observations showed a different spontaneous beating cluster of the 
RyR_X4_KO_CMs compared to control isCPVTb1.6_CMs. RyR_X4_KO_CMs were 
beating slower and the beating pattern was not that synchronized as in control 
isCPVTb1.6_CMs.  
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3.3.1 RyR2 gene expression in RyR2-KO-CMs 
The RyR2_X4_KO-CMs showed unexpectedly contractile functions, even though the 
RyR2 protein was destroyed by the CRISPR/Cas9 system. The CMs were screened at first 
for RyR2 expression on mRNA level. The isCPVTb1.6_X4_RYR2-KO-CMs showed the 
similar level of gene expression for RyR2 as the control isCPVTb1.6-CMs. GAPDH was 
used as a standard reference gene (Figure 22). 
3.3.2  
Figure 22: Gene expression of RyR2 in CRISPR-B-1/Cas9-edited isCPVTb1.6_X4-derived CMs. The CRISPR-
B-1/Cas9 manipulated iPSCs (isCPVTb1.6_X4) and control iPSCs (isCPVTb1.6) were directly differentiated into CMs 
and cultivated up to 90 days. The mRNA was isolated from the CMs and reverse transcribed into cDNA. The 
RyR2_X4_KO-CMs showed the same expression pattern for RyR2 as isCPVTb1.6-CMs. Undifferentiated hiPSCs were 
used as negative control. GAPDH was used as a reference gene and was expressed by all of samples. 
3.3.3 Immunofluorescence staining of RyR2-KO-CMs 
To prove the ability of genetic manipulated isCPVTb1.6_X4 iPSCs to differentiate into 
RyR2-KO-CMs immunofluorescence staining was done. The isCPVTb1.6_X4_RYR2-KO 
-CMs were fixed with 4% paraformaldehyde around day 90. The isCPVTb1.6_X4_RYR2-
KO-CMs were stained simultaneously against the proteins MLC2A and MLC2V, CX43 
and α-actinin (Figure 23), or α-actinin and RyR2 (Figure 24).  
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Figure 23: Immunofluorescence staining of cardiac specific markers MLC2V, MLC2A, CX43 and α-actinin. 
The simultaneous immunofluorescence staining of MLC2A and MLC2V is shown in an overlaid picture with DAPI in 
the first row. The pictures were taken with a 20x image enlargement. The second row shows the simultaneous 
immunofluorescence staining of the gap junction protein CX43 and the z-disc specific marker α-actinin in an overlaid 
picture with DAPI. The pictures were taken with a 63x image enlargement. (Scale bar: 100μm) 
The immunofluorescence staining against CX43 and the z-disc-associated protein α-actinin 
showed that the majority of differentiated RyR2-KO cells were CMs. The 
immunofluorescence staining with the antibodies against MLC2V and MLC2A showed 
that most cells were positive for the ventricular marker MLC2V. Previous study showed 
that MLC2V is ventricular restricted and that MLC2A is highly expressed in the human 
atrium, but at low levels in the human ventricle (Lopes et al. 2006). The 
isCPVTb1.6_X4_RYR2-KO-CMs showed typical protein expression of MLC2V, MLC2A 
and CX43 like normal CMs. 
As expected, immunofluorescence imaging showed no staining of RyR2 located in the SR 
in isCPVTb1.6_X4_RYR2-KO-CMs compared to isCPVTb1.6 iPSC-CMs, assuming that 
the RyR2 protein was not expressed in isCPVTb1.6_X4_RYR2-KO-CMs, however, typical 
sarcomere structures were indicated by α-actinin staining in isCPVTb1.6_X4_RYR2-KO-
CMs similar to control isCPVTb1.6 iPSC-CMs. Control CMs showed a striated pattern of 
RyR2 as well as normal α-actinin staining (Figure 24). The RyR2 protein is responsible for 
the Ca2+ homeostasis in CMs. Nevertheless the isCPVTb1.6_X4_RYR2-KO-CMs showed 
unexpected contractile functions.  
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Figure 24: Immunofluorescence staining of cardiac specific marker α-actinin and RyR2. Immunofluorescence 
imaging showed no staining of RyR2 in RyR2-KO-CMs, but normal sarcomere structures indicated by alpha-actinin 
staining. Control CMs showed a striated pattern of the RyR2 as well as normal alpha-actinin staining. Images were taken 
by Sarah Henze (Scale bar: 100μm) 
3.3.4 Western blot analysis of RyR2-KO-cardiomyocytes 
RyR2-KO-CMs from isCPVTb1.6-X4 were analyzed for RyR2 protein expression via 
Western blot with the antibody recognizing the full length protein of RyR2. CMs derived 
from the origin iPSC line isCPVTb1.6 were used as control. Whereas the RyR2 protein was 
detected in CMs derived from the control cell line isCPVTb1.6, Western blot analysis 
showed no detectable RyR2 protein in RyR2-KO-CMs. CTNT was used to determine the 
CM proportion and no obvious differences could be detected in CM amount in the 
different samples (Figure 25). This analysis further confirmed the successful generation of a 
RyR2 protein knockout iPSC line. 
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Figure 25: Western blot analysis of the RyR2 protein in RyR2-KO-CMs. The RyR2 protein was not detectable in 
RyR2-KO-CMs. The KO cell line from one iPSC patient was tested (CPVTb1.6-X4) with the antibody recognizing the 
full length protein of RyR2 (α-RyR2 mouse). cTNT was used to determine the CM proportion.  Images were taken by 
Sarah Henze. 
3.3.5 Calcium imaging of RyR2-KO-CMs 
Confocal calcium imaging offers optical tracking of Ca2+-transients in cells via fluorescence 
linked signal recognition.  Ca2+ plays a crucial role for the CM contraction. An untypical 
Ca2+ homeostasis in the KO-CMs derived from isCPVTb1.6_X4 iPSC line was expected, 
because of the non-expression of RyR2. RyR2 plays a crucial role during the Ca2+ 
homeostasis. It releases Ca2+ from the SR into the cytoplasm during a contractile phase, 
which is essential for the contraction induced by high intracellular Ca2+ concentration. The 
KO-CMs differentiated from isCPVTb1.6_X4_RYR2-KO iPSC line were examined for 
their calcium cycling characteristics.  
The KO-CMs from the cell line isCPVTb1.6_X4 as well as CMs from the control 
isCPVTb1.6 were examined around day 90. Fluo-4/AM- a calcium-sensitive dye, was used 
during the confocal laser scanning microscopy to test the calcium cycling characteristics of 
the CMs. Calcium sparks during calcium imaging are the microscopic release of Ca2+, 
which corresponds approximately with the Ca2+ release from the SR especially via RyR2 
into the cytoplasm during diastole.  
The calcium imaging of RyR2-KO-CMs showed no calcium sparks when they were paced 
at 0.25 Hz in comparison to the control CMs (isCPVTb1.6-Control). This confirms the 
absence of a defect RyR2 like in CMs derived from CPVT patients.  
Ca2+ transients were measured by confocal line scan imaging. RyR2-KO-CMs showed 
smaller amplitudes and a slower decrease to baseline in comparison to the control CMs, 
when they were stimulated with 0.25 Hz. (Figure 26).  
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Figure 26: Calcium imaging of RyR2-KO CMs. All CMs were loaded with fluo-4/AM around day 90 and were 
stimulated with 0.25 Hz. No calcium sparks were detected in the RyR2-KO-CMs stimulated with 0.25Hz. The control 
CPVT-CMs showed Ca2+sparks under stimulated conditions. Ca2+transients were shown by the use of confocal line scan 
imaging. The amplitudes of the Ca2+ transients were smaller and the decrease of the Ca2+ to baseline was slower in RyR2-
KO CMs (red graph) compared to the data of the control-CMs (black graph Images were taken by Sarah Henze and 
Lukas Cyganek 
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4 Discussion 
CPVT is a genetic cardiac disorder leading to sudden cardiac death in young patients 
without structural abnormalities of the heart. Over 150 mutations in the RyR2 gene causing 
CPVT1 have been identified so far (Lehnart et al. 2008). Thereof, several mutations have 
been studied in either transgenic mice or cell models. Abnormal Ca2+ handling in CMs 
causes severe arrhythmia during physical or emotional stress through missense mutations 
in the RyR2 or CASQ2 gene (Jiang et al. 2002; Cerrone et al. 2009). 
The aim of the thesis was to establish an in vitro disease model using hiPSCs from CPVT1 
patients. The patients carry a heterozygous missense mutation in the RyR2 gene. Two iPSC 
lines (isCPVTc2.2 and isCPVTc2.3) from one CPVT patient, who was heterozygous for a 
point mutation in the RyR2 gene (E4076K), were characterized for their pluripotency 
within this study. According to the standardized pluripotency characterization procedure, 
pluripotency-associated markers were shown on both mRNA and protein level. Germ 
layer-specific markers were shown as well on protein level.  
The second aim was to correct a point mutation in the RyR2 gene from a second patient 
(A2254V) and to create a knockout cell line of the RyR2 protein via CRISPR/Cas9-based 
genome editing. 68 cell clones were tested for genome editing after hiPSC transfection and 
expansion. One CRISPR/Cas9 targeted cell clone (X4) had four homozygous nucleotide 
deletions on both alleles of the genome causing a frame shift, which finally resulted in a 
premature stop codon in the RyR2 gene. The point mutation A2254V in the RyR2 gene 
was corrected as well. By this way, we have not only managed to correct the point mutation 
in the RyR2 gene, but also managed to create a RyR2-KO hiPSC line. However, we have 
not been able to create a corrected RyR2 cell line alone. The engineered RyR2-knockout 
hiPSC line was examined for pluripotency-associated markers and differentiated into 
functional CMs for further analysis. The RyR2-KO-CMs showed no detectable RyR2 
protein expression, which was shown by using Western blot analysis. In addition, an 
analysis of the Ca2+ handling in the RyR2-knockout CMs was performed and the results 
were compared to control CPVT-CMs. The RyR2-KO-CMs showed no Ca2+ sparks under 
stimulated conditions with 0.25 Hz in comparison to the control CPVT-CMs, which 
showed the CPVT-specific Ca2+ sparks via Ca2+ imaging.  
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4.1 Establishing hiPSCs from CPVT patients 
Yamanaka’s work in 2006 and 2007 was a breakthrough for the medical world. It laid the 
foundation for the generation of hiPSCs from somatic cells by reprogramming them with 
defined factors (Takahashi and Yamanaka 2006; Takahashi et al. 2007). HiPSCs are used 
for patient specific disease models and for therapeutic applications as well as in drug 
discovery and in regenerative medicine.  
The CPVT iPSC lines used in this study were generated by reprogramming of fibroblasts 
from the CPVT-patients with the SeV through the overexpression of the four Yamanaka 
factors OCT4, SOX2, KLF4 and C-MYC. SeV was chosen due to its replication, which 
takes place exclusively in the cytoplasm of infected cells. This in turn minimizes the risk of 
unwanted integration into the host genome (Li et al. 2000). By this way, the generated 
hiPSCs were transgene-free (Fusaki et al. 2009).   
The process of reprogramming somatic cells to hiPSCs is currently not fully 
comprehensible. It contains the suppression of somatic cell-specific genes and the 
activation of pluripotency specific transcription network. A change in the metabolic system 
from oxidative phosphorylation in somatic cells to a glycolysis-based metabolism in hiPSCs 
and a mesenchymal to epithelial transition are additionally induced (Samavarchi-Tehrani et 
al. 2010; Zhang et al. 2012). In this study, the isCPVTc2.2 and isCPVT2.3 iPSCs are 
proved to be positive for the transcription factors like the “core factors” OCT4, NANOG 
and SOX2 and additionally LIN28, FOXD3, GDF3, SSEA4 and TRA-1-60, which are 
necessary to maintain pluripotency in hESCs and hiPSCs. The maintenance of the 
pluripotency network of ESCs and hiPSCs is based on the expression and activation of the 
transcription factors including OCT, SOX2 and NANOG (Boyer et al. 2005). SOX2 and 
OCT4 bind DNA co-operatively to activate the transcription of key pluripotency factors. 
Both factors maintain their own expression through a feedforward auto-regulatory loop of 
pluripotency (Chambers and Tomlinson 2009). NANOG functions in combination with 
OCT4 in order to maintain pluripotency and to sustain self-renewal of ESCs (Cavaleri and 
Schöler 2003; Chambers et al. 2003). NANOG and KLF4 have common targets and are 
important for the self-renewal as well as the regulation of the transcription of pluripotency 
factors (Jiang et al. 2008). The reprogramming of somatic cells is not fully dependable on 
C-MYC but its expression plays an important role in increasing the reprogramming 
efficiency. C-MYC influences cell proliferation, biosynthetic pathways and metabolism 
(Nakagawa et al. 2010; Nakagawa et al. 2016).   
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Other factors as LIN28, FOXD3, GDF3, SSEA4 and TRA-1-60 are also highly expressed 
in hESCs and down-regulated in differentiated cells (Boyer et al. 2005; Kim et al. 2008). 
The generated hiPSCs in this study showed the same characteristics as hESCs. The 
morphology and the ALP expression as well as the mRNA expression of pluripotency- 
associated markers like OCT4, SOX2, NANOG, LIN28, FOXD3 and GDF3 were 
comparable to the characteristics of hESCs. Additionally, OCT4, SOX2, LIN28, NANOG, 
SSEA4 and TRA-1-60 were expressed on protein level. These characteristics show that the 
ectopic expression of OCT4, SOX2, KLF4 and C-MYC during reprogramming activated 
the expression of endogenous pluripotency genes and proteins, which were maintained 
during long-term culture (Kim et al. 2008; Fusaki et al. 2009). 
An important characteristic of hiPSCs is the potential to differentiate into derivatives of all 
three germ layers (Itskovitz-Eldor et al. 2000; Sheridan et al. 2012). The expression of 
specific markers for each of the three germ layers was shown after spontaneous in vitro 
differentiation of the CPVT-hiPSCs on protein level, which ultimately demonstrates that 
the cells are pluripotent. The expression of the associated germ layer-specific marker on 
mRNA level could not have been shown, due to a laboratory mistake in the spontaneous 
mass culture experiment. This experiment should be repeated in the future to fulfill the 
standardized characterization of the isCPVTc2 cell lines. 
To verify the cell line identity, patient-specific isCPVTc2.2 and isCPVTc2.3 lines were 
sequenced in the lab before starting the thesis work. The previous sequencing confirmed 
the heterogeneous missense mutation in the RyR2 gene (E4076K) (data not shown). 
In summary, the analyzed two CPVT-hiPSC lines (isCPVTc2.2 and isCPVTc2.3) have 
similar characteristics as hESCs and meet the standards of fully reprogrammed hiPSCs.  
4.2 CRISPR/Cas9 
CRISPR/Cas9 systems originally function as an adaptive immune system in bacteria against 
viral DNA, plasmids or foreign RNA. The systems have been adapted to genome 
engineering tools, which are able to generate DSBs in predicted regions of the eukaryotic 
genome in order to generate either knock-outs or knock-ins and to correct endogenous 
genetic mutations. To the current state of research it is the most efficient technology for 
genome editing (Garneau et al. 2010; Jinek et al. 2012; Doudna and Charpentier 2014).  
CRISPR/Cas9 was chosen in this project for genome editing because of the broad 
advantages in comparison to ZNF and TALEN. The major advantage of the 
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CRISPR/Cas9 technology is the simplicity of the target design. The DNA-binding moiety 
in CRISPR/Cas9 uses RNA, whereas ZFN and TALEN use protein, which makes the 
design more complex. Also, the costs for the CRISPR/Cas9 technology are much lower in 
comparison to ZNF and TALEN, caused by the simplicity of the CRISPR/Cas9 design 
and the possibility to use standard cloning procedures and oligo syntheses to multiply the 
system. A further advantage of the CRISPR/Cas9 technology is the possibility to introduce 
multiple DSBs in the same cell via expression of distinct guide RNAs, which is called 
multiplexing (Kabadi et al. 2014).  
The ability to design custom-specific CRISPR/Cas9 complexes offers the opportunity to 
manipulate biological organisms on almost every arbitrary location of the genome. On the 
one hand, this renders the opportunity for a potential treatment of genetic disorders by 
correcting disease-causing mutations. On the other hand, the potential for unethical genetic 
manipulations, which is causing a huge discourse in the society (Musunuru 2017) could be 
an outcome. The CRISPR/Cas9 complex is guided by a 20-nucleotide crRNA, which is 
complementary to the targeted DNA sequence in a defined location where the DSB should 
occur. The DSB is repaired either by NHEJ or by HDR repair mechanisms. The repair of 
the broken DNA by NHEJ might introduce unspecific small indel. Conversely the HDR 
repair mechanism leads to a targeted genetic correction or manipulation in the presence of 
a donor DNA plasmid or ssODN flanking the DSB site (Sander and Joung 2014).  
We established a protocol for the use of CRISPR/Cas9 to manipulate isCPVTb1.6 iPSCs. 
The isCPVTb1.6 hiPSCs were transfected with ssODNs and a CRISPR/Cas9 combined 
plasmid. The aims of this experiment were primarily to create a frameshift in the RyR2 
gene by unspecific deletions via NHEJ to create homozygous RyR2 knockout cell lines and 
secondly to correct the point mutation (A2254V) in the RyR2 gene causing the disease 
phenotype by HDR. This should prove the hypothesis that the observed CPVT-phenotype 
in isCPVTb1.6 iPSC-CMs is caused by the point mutation in the RyR2 gene and can be 
annihilated in CRISPR/Cas9 corrected CMs. 
A 20 bp sequence in close proximity to the intended DSB was chosen for a successful 
binding of the CRISPR/Cas9 complex on the DNA guided by a gRNA. The ssODNs were 
designed as a template, which contains the corrected sequence for the genetic correction of 
the point mutation via HDR. Ideally, the mutation should be in close proximity (<20 bp) 
to the targeted site of the nuclease to guarantee high targeting frequencies (Hsu et al. 2013). 
In this study, the gRNA was designed with the help of an online tool to minimize the 
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mismatch and off-target activity. The mismatch activity was predicted to be low. Two off-
target sites where detected. The PAM was 34 bp close to the targeted site. The gRNA was 
included into the CRISPR plasmid construct and ordered at Sigma Aldrich. 
A mismatch-specific endonuclease assay was performed to measure the direct RyR2 
interruption induced by the designed CRISPR/Cas9 plasmid. The cleavage efficiency was 
around 15-20%, which resembles the value of the positive control of the kit. One of the 
key limitations for successful CRISPR/Cas9 experiments in human cells is that they prefer 
to take the NHEJ pathway to repair a DSB instead of using the precise HDR pathway 
(Chapman et al. 2012). The amount of successful CRISPR-mediated gene knockout 
experiments via NHEJ-induced indel mutations predominates the amount of successful 
precise corrections of point mutations or introductions of sequence fragments via HDR in 
hiPSCs. Only a few working groups have been able to correct missense mutations in 
hiPSCs by using CRISPR/Cas9 (Chang et al. 2015; Huang et al. 2015; Tang et al. 2016; 
Turan et al. 2016).  
These groups used either plasmids containing the designed CRISPR/Cas9 complex and the 
gRNA and ssODNs, which were transfected into iPSCs via nucleofection, or adenoviral 
mediated genome editing. For our gene editing experiments, we used ssODNs together 
with CRISPR/Cas9 plasmids to induce HDR. The transfection efficiency after 
nucleofection was below 5%, which is typical for hiPSCs as a difficult-to-transfect cell type. 
However, the positive-transfected CPVT-hiPSCs could be sorted by an additional GFP 
signal within the plasmid. FACS was used to select the GFP+ cells. Just a small amount of 
transfected CPVT-hiPSCs survived the cell sorting, which was limiting the experiment. In 
spite of the low transfection efficiency and the low survival rate, 68 iPSC clones were 
screened after hiPSC transfection and after cell sorting and expansion. One of the reasons 
for the low survival rate after the transfection of the hiPSCs could be the After-FACS 
medium, which may have too less nutrients. A more nutrient hiPSC medium like 
StemMACS iPS Brew XF medium could be used in future experiments in order to increase 
the survival rate of the transfected hiPSCs by inducing a faster recovery after stressful 
situations. Valamehr’s working group had a higher survival rate while using a survival 
cocktail with different small inhibitors compared to our results with the single use of TZV 
(Valamehr et al. 2012). A combination of these two approaches could be the key for a 
higher survival rate after nucleofection in future experiments. A further troubleshooting 
event for the low survival rate could be the quantity and quality of the Cas9 and sgRNA 
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plasmid, which was produced with maxiprep. It is essential to ensure a high concentration 
of the plasmid > 2mg/ml and that endotoxin-free materials are used. If there is a 
difference in the survival of the transfected and control cells, the DNA quantity needs to 
be controlled. Furthermore the sg RNA should not target a gene which is essential for cell 
survival, which leads to troubleshooting events (Byrne and Church 2015). 
Our results showed that <4% of the cell clones, which were analyzed by PCR and 
restriction digestion, displayed a genomic modification.  
After PCR and restriction enzyme digestion with SpeI, one sequenced clone 
isCRISPR_CPVTb1.6_X4 had a ssODN based sequence in its genome. The clone had 
additionally integrated indels in the RyR2 gene besides the desired correction of the point 
mutation.  The second sequenced clone isCRISPR_CPVTb1.6_X2 had integrated indels 
earlier in the genome, leading to a complete destruction of the RyR2 gene.  One possibility 
is that CRISPR/Cas9 could cleave the DNA again after a first HDR-mediated genomic 
correction. Some studies showed an increase of HDR efficiency without further indels by 
using ssODNs with silent missense mutations to prevent inadvertent cleaves by 
CRISPR/Cas9 after HDR (Paquet et al. 2016). Our study failed to confirm this hypothesis 
after using a new designed ssODN with a silent missense mutation. We were not able to 
cultivate a single clone using the new designed ssODNs.  
In addition, because of the failure to create a clone with an isolated genetic correction 
instead of additional unspecific indels, we assume that HDR works inefficient in hiPSCs. 
The use of small molecules to increase the efficiency of CRISPR/Cas9 mediated gene 
editing in hiPSCs improved the amount of HDR after DSB in diverse studies (Maruyama et 
al. 2015; Yu et al. 2015).  
The major challenge of the CRISPR/Cas9 technology is the high off-target activity. In 
comparison to other gene editing technologies like TALEN, CRISPR/Cas9 shows a higher 
and unspecific off-target activity (Frock et al. 2015). Several working groups are 
investigating new approaches to reduce the off-target activity to push the technology ahead 
to clinical standards for disease treatment without unspecific off-target mutagenesis. An 
approach to reduce the off-target activity of the CRISPR/Cas9 plasmid is a better design of 
the sgRNA. Half of the human genome consists of repeated sequences concluding that a 
high specificity of the sgRNA is needed to sustain minimal off-target activity. To achieve a 
minimal off-target activity, the use of web-based bioinformatics tools and algorithms was 
established. However, the use of these tools has limitations. The off-target activity and the 
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cleavage activity are influenced by many factors, which delimitate the predictions of the 
algorithms. Pelletier’s group showed that the use of sgRNA with a PAM-distal 
complementary and with a minimum guide length of 17 nucleotides reduces the off-target 
activity and engaged the Cas9 targeted cleavage. The sequences distal to PAM should 
trigger a conformational change of Cas9 to boost the CRISPR/Cas9 DNA target cleavage 
(Cencic et al. 2014). However, the possible mismatch tolerance of Cas9-sgRNA complexes 
fosters the off-target cuts in the genomic DNA. Although we ordered a custom designed 
CRISPR/Cas9 plasmid at Sigma-Aldrich with low predicted off-target effects via 
bioinformatics tools, a tolerance of mismatches exists. The state of science is the avoidance 
of off-target activity for a precise genome editing (Hsu et al. 2013; Cho et al. 2014; O’Geen 
et al. 2015; Zhang et al. 2015). Another strategy to reduce off-target activity is to weaken 
interactions between Cas9 and the non-complementary DNA strand. A positive electric 
cloud is formed among the minor binding channel of the nuclease (NUC) lobe and creates 
a pulling force of the NUC lobe. The NUC lobe is elementary to separate the non-target 
DNA from the gRNA-target DNA heteroduplex while unwinding the double strand 
protospacer DNA and during the formation of the gRNA-target DNA heteroduplex. 
CRISPR-Cas9 DSB specificity changes, if there are modifications in the positively charged 
amino acids of the NUC lobe. This changes the positive electric density along the minor 
binding channel of the NUC lobe. A balanced system needs to be designed. Pulling forces, 
which are too strong, as well as weak pulling forces result in a higher off-target DSB 
activity through a misbalanced interaction between the gRNA and the non-target DNA. 
Due to positive charged amino acids the pulling force is strong and weakens the hydrogen 
bonds between the two strands of the protospacer DNA. The detachment of the gRNA 
from the non-target DNA becomes easier and the formation of a heteroduplex with the 
target DNA strand is favored. The outlook is a systematical identification of amino acids 
responsible for each base pair position of the protospacer sequence for targeted 
engineering of each DNA site with almost no off-target activity (Slaymaker et al. 2016; 
Zhang et al. 2016).  A further approach is the use of SpCas9-HF1, a high-fidelity variant 
harboring alterations designed to reduce non-specific DNA contacts. Joung’s working 
group showed data with almost no off-target activity in comparison to the standard 
SpCas9. The high-fidelity variant can be used to target non-repetitive sequences that do not 
have closely matched sites elsewhere in the genome (Kleinstiver et al. 2016). 
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Avoiding off-target activity is necessary for future in vitro and especially in vivo studies and 
therapeutic use of CRISPR/Cas9 to eliminate the risk of off-target mutagenesis (Lee et al. 
2016a). This can be achieved by a specific design, accessibility of sgRNA and an 
identification of amino acids responsible for each base pair positon of the protospacer 
sequence. A gRNA truncation and a gRNA elongation is discussed to reach a lower off-
target activity and a higher on-target activity (Kim et al. 2015). By increasing the overall 
length from 20 to 40 bp a higher specificity for the Cas9 nickases can be reached (Tsai et al. 
2014). Furthermore Cas9 orthologs with different PAM requirements for example with 
longer PAM sequences as Staphylococcus aureus Cas9, Streptococcus thermophilus Cas9 
and Neisseria meningitidis Cas9. These Cas9 orthologous have been already adopted for 
genome editing in mammalian cells and a lower off-target activity was detected (Ran et al. 
2015; Lee et al. 2016b; Müller et al. 2016).  
4.3 Generation of  CMs out of  CRISPR/Cas9 targeted hiPSCs 
In this study we have not been able to correct the missense mutation in the RyR2 gene in 
hiPSCs derived from the CPVT patient b1. The designed CRISPR/Cas9 vectors 
introduced additionally indels after HDR. However, this resulted in a successful genetic 
alteration in the RyR2 gene, which was the second aim of our protocol. The CRISPR/Cas9 
targeted hiPSC clone displayed a correction of the mutation and an additional homozygous 
deletion in the RyR2 gene, which was confirmed by genetic sequencing. The deletion of 4 
bps caused a frameshift of the coding sequence and resulted in a premature termination 
codon and a truncated RyR2 protein.  
The CRISPR/Cas9 targeted CPVT-hiPSCs were examined for the maintenance of 
pluripotency after genetic manipulation. The CRISPR/Cas9 targeted CPVT-hiPSCs 
showed similar characteristics like the patient-specific iPSCs or hESCs. The morphology 
and ALP activities and the mRNA expression of pluripotency related markers like OCT4, 
SOX2, NANOG, LIN28, FOXD3 and GDF3 were comparable to parental isCPVTb1.6 
iPSC and hESC characteristics. Additionally, OCT4, SOX2, LIN28, NANOG, SSEA4 and 
TRA-1-60 were expressed on protein level. The expression of the pluripotency related 
markers on mRNA and protein level showed that there was no manipulation of the 
pluripotency characteristics in the CRISPR/Cas9-targeted CPVT-hiPSCs after genomic 
editing. 
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Based on our literature research, no knockout hiPSC line of the RyR2 gene exists so far. 
The RyR2 function was usually analyzed in mouse knockout models instead of in hiPSC-
derived CMs. Takeshima et al. showed in 1998 that mice with a homozygous deletion of 
RyR2 had an embryonic lethality around day 10 through cardiac arrest (Takeshima et al. 
1998). This leads to the assumption that functional RyR2 is essential for mammalian 
survival. Heterozygous mice had alterations in ECG recordings and membrane potential 
measured in urinary bladder smooth muscle cells (Hotta et al. 2007). Bround et al. showed 
that adult mice developed brachycardiac and intermittent tachycardiac arrhythmias after 
reducing the amount of RyR2 in an inducible cardiac-specific heterozygous knockout mice 
model (Bround et al. 2012). These studies show that RyR2 is essential for a normal cardiac 
function and thus demonstrate the importance of a better understanding of its function for 
future drug targets. The translation from mouse models to human models is limited. The 
animal model CMs for in vivo studies display major differences in cellular electrophysiology 
and limitations in predicting drug responses compared to human CMs.  This animated us 
to create hiPSC-derived CMs from the generated homozygous RyR2-KO-hiPSCs 
(isCPVTb1.6_RyR2_X4_KO) for further investigation of the RyR2 function and possible 
adaption and compensation mechanisms in the Ca2+ cycling. 
The RyR2-KO-hiPSCs were differentiated into CMs according to our standardized 
protocol, which imitates the embryonic developmental signals. First, activation of the 
WNT signaling pathway induced mesoderm formation. Inhibiting the WNT, BMP and 
TGFβ pathways induced the cardiac specification subsequently (Burridge et al. 2011; 
Kattman et al. 2011).  
CMs were selected around day 20 through metabolic selection, where glucose was replaced 
with lactate for 4-6 days to obtain a high amount of pure CMs (Tohyama et al. 2013). 
Glucose deprivation gains the proportion of pure CMs from 85% TNNT2+ to >95%, 
which is beneficial for further analyses (Burridge et al. 2014). Experiments without 
metabolic selection showed a high amount of CMs overgrown with neural or fibroblast-like 
cell types. The generated CMs were cultivated up to day 90 to reach a higher maturation 
phenotype resembling CMs at fetal stages, assuming that the characteristics of iPSC-CMs 
could correlate with the characteristics of heart muscle cells of CPVT patients. CPVT 
patients develop first symptoms during childhood and young adolescence, when the 
embryonic development of the heart is already completed. Our aim was to compare the 
RyR2-KO-CMs with CMs derived from CPVT patients without genetic manipulation. The 
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RyR2-KO-CMs showed an aberrant beating cluster compared to CPVT-CMs. The beating 
was slower and displayed a delayed onset of first contractions during cardiac 
differentiation. The data of this study showed that RyR2-KO-CMs had no difference in 
RyR2 mRNA expression compared to the corresponding CPVT-CMs, whereas on protein 
level RyR2 was not detectable in CRISPR/Cas9-edited CMs in comparison to CPVT-CMs 
assessed by Western blot analysis. Both RyR2-KO-CMs and CPVT-CMs showed 
comparable expression of typical cardiac markers like MLC2v, MLC2A, α-ACT, and CX43 
and displayed well-organized sarcomeric structures. CX43 was used as a marker for gap 
junctions, which are important for cell-to-cell contact and electrical signals between CMs. 
The expression of sarcomere and gap junction proteins, which are elementary for the 
cardiac function, in RyR2-KO-CMs was comparable to the expression in CPVT-CMs. Only 
RyR2 was not detectable on protein level in RyR2-KO-CMs, whereas α-ACT as a marker 
for cross-striation was detectable by immunofluorescence staining. The conclusion based 
on this data is that the frame shift induced a fully degraded RyR2 protein in RyR2-KO-
CMs.  
Against our expectations, RyR2-KO-CMs contract after cardiac differentiation. Functional 
analyses via calcium imaging showed that no uncontrolled Ca2+ sparks were detectable in 
RyR2-KO-CMs, whereas CPVT-CMs showed typical Ca2+ sparks, when they were 
stimulated with 0.25Hz during Ca2+imaging. The amplitudes of Ca2+ transients in RyR2-
KO-CMs were smaller compared to the amplitudes of the control CPVT-CMs (Henze 
2016). The calcium transients displayed a different shape leading to the assumption that 
IP3 or different Ca2+ homeostasis proteins regulate the Ca2+ release. This results in a 
different Ca2+ homeostasis pattern compared to the physiological RyR2-mediated Ca2+ 
release. The small amplitudes of the Ca2+ transients in RyR2-KO-CMs could be a result of a 
failure in the Ca2+ release from the SR through RyR2. We speculate that compensatory 
mechanisms might regulate the Ca2+ homeostasis in CMs without the RyR2 protein. CMs 
need to adapt the expression of Ca2+ regulatory proteins to compensate for the loss of 
function of the RyR2. One hypothesis is that CMs generated from hiPSCs resemble 
immature CMs with an immature functioning of the SR in terms of their Ca2+ handling 
compared to adult CMs (Lee et al. 2011). During early cardiogenesis, IP3 is upregulated 
already at day 5.5 whereas RyR2 upregulation does not begin until day 8.5 in mouse 
models. IP3 is responsible for the Ca2+ homeostasis in early CMs (Rosemblit et al. 1999). 
The IP3-gated Ca2+ release may compensate for the function of the missing RyR2 in RyR2-
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KO-CMs. This Ca2+ release is sufficient to induce the cardiac contraction in early stage of 
cardiogenesis (Janowski et al. 2010). Supporting the hypothesis that IP3 compensates for 
the RyR2 function, Go et al. showed that RyR2 is downregulated and IP3 is upregulated 
during end-stage heart failure when fetal gene programs are reactivated as a compensatory 
response (Go et al. 1995). Further compensatory mechanisms could be the activation of 
the Fas signaling pathway as observed in heart failure patients. The Fas receptor activation 
induces the phospholipase C, which activates 1,4,5-IP3 leading to a Ca2+ release from the 
SR (Barac et al. 2005). The role of mitochondrial Ca2+ release is not fully understood yet, 
but it could be a further mechanism to resemble the loss of function of RyR2It is 
postulated that Ca2+ and ROS release from the mitochondria can be induced through direct 
protein-protein interaction initiated by shear/flow forces. The mitochondrial Ca2+ release is 
a response to mechanical forces like the cell contraction (Beutner et al. 2001; Belmonte and 
Morad 2008). NCX1 is a Na+/Ca2+ exchanger protein, which is able to function in forward 
and reverse modes. In reverse mode, NCX1 is capable of Ca2+ influx. In early cardiogenesis 
NCX1 functions in reverse mode. Through the Ca2+ influx, NCX1 has a major role in 
generating the Ca2+ transient at the earliest stage of cardiac contraction (Iwamoto 2004). 
The NCX1 may compensate for the RyR2 function in early stage of cardiogenesis, when a 
functional SR is not yet required and the Ca2+ homeostasis is regulated by NCX1 and other 
proteins (Tyser et al. 2016). Future investigation should be performed to figure out which 
compensatory mechanisms occur in RyR2-KO-CMs. 
Heart failure studies with animal models and human heart tissue showed significant 
changes in the expression of proteins associated with the excitation-contraction coupling. 
The RyR2 expression is decreased by up to 25% in rabbit or up to 30% in canine models 
of aortic insufficiency, 48% in a canine model of chronic heart failure by pacing and 35% 
in human heart failure (Go et al. 1995; Ai et al. 2005; Kubalova et al. 2005; Song et al. 
2005). These studies lead to the assumption that the compensatory mechanisms in these 
models could be comparable to our knockout model. The expression of SERCA is 
suppressed and the degree of the damage could correlate with the severity of symptoms 
seen in human failing compared to non-failing hearts (Hasenfuss et al. 1994). In addition, 
the NCX expression in heart failure patients is increased. The exact function of the NCX 
in human heart failure has not yet been definitely established. The Ca2+ influx via the NCX 
can increase the SR Ca2+ content in CMs. These effect was shown in CMs from infarcted 
hearts with a modest NCX activity (Litwin and Zhang 2006). The combination of increased 
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NCX and decreased SERCA expression leads to increased cellular extrusion and a 
decreased Ca2+ store in the SR (Hasenfuss et al. 1994; Reinecke et al. 1996; Litwin and 
Zhang 2006). This limits the cytosolic Ca2+ available for contractile protein maintenance 
(Blayney and Lai 2009).  
Further investigation of possible compensatory mechanisms for the loss of function of the 
RyR2 in RyR2-KO-CMs could aid our understanding of molecular mechanisms controlling 
calcium handling during early cardiogenesis and in human heart failure. 
4.4 Conclusions and outlook 
The findings of this study underlie that patient-specific hiPSCs are a promising tool for 
studying human diseases and for detailed investigation of mutations in the RyR2 gene of 
CPVT patients. A RyR2 knockout model for a better understanding of the RyR2 channel 
and the Ca2+ homeostasis in CMs complemented the CPVT disease model. CPVT-hiPSCs 
were successfully characterized and differentiated into ventricular-like CMs. The 
establishment of these protocols was essential for further investigations especially for the 
CRISPR/Cas9 assisted genome editing in hiPSCs and the following differentiation into 
CMs. 
CRISPR/Cas9 systems were used for genome editing in hiPSCs derived from one CPVT 
patient. CRISPR/Cas9 edited hiPSCs were generated, yet it was not possible to create 
isogenic corrected controls of the hiPSCs derived from the CPVT patient. 
A further approach to prove the concept of the disease phenotype of a specific point 
mutation would be to introduce the mutation in healthy hiPSCs to generate heterozygous 
hiPSCs with the mutation and study the mutation-specific phenotype. These genetic 
manipulated cells could be compared with CPVT-patient derived hiPSCs. The primary 
recruiting of CPVT-patients would not be necessary and it would be easier and faster to 
create more mutations in the RyR2 gene. The big disadvantage of this study design is that 
the cells would not be patient specific anymore, which does not take the patient-specific 
genetic factors into account and not fit well with the approach of personalized medicine. 
Furthermore, new experiments could be designed using new approaches to reduce the re-
cutting possibility and the off-target activity in CRISPR/Cas9 systems. 
A homozygous CRISPR/Cas9-edited hiPSC line with a complete knockout of the RyR2 
protein was generated in this study. The isCPVTb1.6_RyR2_X4_KO-CMs show no 
detectable expression of the RyR2 protein. CMs derived from isCPVTb1.6_RyR2_X4_KO 
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have altered Ca2+ transients with respect to amplitude and shape. The RyR2_X4_KO-CMs 
are a useful model for further studies to examine the Ca2+ homoeostasis in these CMs with 
a loss of the RyR2 protein. The Ca2+ homoeostasis can be compared with the Ca2+ 
homeostasis in CMs of patients with severe heart failure or with the Ca2+ homoeostasis 
during early CM differentiation because of the modified expression profile of calcium 
channel proteins during cardiogenesis. The future understanding of the compensatory 
mechanisms of the genome-edited CMs can lead to a better understanding of the RyR2 
function.  
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5 Abstract 
CPVT is a genetic cardiac disorder leading to sudden cardiac death in young patients 
without structural abnormalities of the heart. Abnormal Ca2+ handling in CMs causes 
severe arrhythmia during physical or emotional stress through missense mutations in the 
RyR2 or CASQ2 gene. Over 150 mutations in the RyR2 gene causing CPVT1 have been 
identified so far. The exact underlying pathomechanism causing a typical disease pattern 
induced by point mutations is not yet fully explored. The objective of this research is to 
contribute to the establishment of in vitro disease models for CPVT with hiPSCs as a source 
for CMs. 
CPVT disease models of this project were based on hiPSCs from CPVT patients b1 and 
c2, who respectively had a missense mutation A2254V or E4076K at different loci.  In this 
study pluripotency was proven in hiPSCs from CPVT patient c2. The differentiation 
potential of hiPSCs into all three germ layers ectoderm, mesoderm and endoderm was 
verified as well. The hiPSCs from CPVT patient b1 were characterized in previous studies.  
For further investigation of the point mutation-based phenotype in CPVT patients 
CRISPR/Cas9 technology was applied for genome editing in hiPSCs from the CPVT 
patient b1. The study failed to fulfill the aim to correct the single point mutation in hiPSCs 
from patient b1 to generate an isogenic corrected control cell line. Nevertheless, 
homogeneous CRISPR/Cas9-edited hiPSCs with a knockout of the RYR2 protein were 
generated, characterized for pluripotency-associated marker and differentiated into CMs. 
The CRISPR/Cas9-edited CMs with homozygous deletions in RYR2 showed normal 
RYR2 mRNA expression, but no expression of the RYR2 protein. The CRISPR/Cas9 
edited CMs showed a typical expression pattern for the remaining cardiac marker on 
mRNA and protein level. Surprisingly, RyR2_X4_KO-CMs were able to contract without 
the expression of RYR2 protein compared to the control CPVT-CMs and showed no 
CPVT typical Ca2+ leak.  
In conclusion, the data of this study show that patient-specific hiPSCs are useful tools to 
create CPVT disease models. Even though an isogenic corrected control cell line could not 
be generated in this study, CRISPR/Cas9 systems are a promising tool for genetic 
manipulation in hiPSCs. 
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RyR2_X4_KO-CMs offer the possibility to analyze the compensatory adaption mechanism 
for a sufficient Ca2+cycling without functioning RYR2 protein. As a result, future drug 
targets can be developed. 
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